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A large proportion of chlamydial and gonococcal infections are asymptomatic. In lower- and 
middle-income countries like South Africa, where syndromic management is practiced, it is 
likely that a large proportion of curable sexually transmitted diseases (STIs) go untreated, as 
screening for asymptomatic STIs is rarely conducted. Due to the lack of empirical data on the 
effectiveness of STI screening programs, dynamic mathematical modelling has been used to 
assess the impact of screening, although most previous modelling studies have focused on 
high-income settings. Here we utilize dynamic mathematical modelling to evaluate the 
potential impact of opportunistic STI screening programs on the incidence and prevalence of 
Chlamydia trachomatis and Neisseria gonorrhoea in South Africa. We extended an existing 
agent-based model of heterosexual HIV and STI transmission in South Africa to investigate the 
impact of targeted screening strategies directed at high risk groups including youth, female 
sex workers, pregnant women and patients in HIV care. All four screening strategies resulted 
in reductions in general and key population STI transmission. Opportunistic STI screening of 
youth and ART patients were shown to be most effective and represent viable interventions 
for reducing STI transmission in the South African population. Additionally, we compared the 
modelled impact of a standardized screening program to results obtained from other 
published mathematical models of chlamydia screening. Differences between models could 
be attributed to differences in the modelled heterogeneity in sexual behaviour as well as 
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Bacterial sexually transmitted infections (STIs) are a major contributor to the global burden 
of disease, especially in developing countries with limited resources for diagnosis and 
treatment (1). If undiagnosed or untreated, sexually transmitted bacterial infections such as 
Chlamydia Trachomatis (CT) and Neisseria gonorrhoeae (NG) can result in serious 
reproductive problems including pelvic inflammatory disease (PID), ectopic pregnancy and 
infertility in women (2) as well urethritis and epididymitis (3) in men. Bacterial STIs during 
pregnancy are associated with pre-term delivery and a range of adverse birth outcomes such 
as low birth weight and post-partum endometritis (4). CT and NG can be transmitted 
perinatally causing inclusion infant conjunctivitis, pneumonia and in some cases, neonatal 
death (4).  As well as being a significant contributor to morbidity in their own right, bacterial 
STIs have been shown to increase the risk of both the transmission and acquisition of Human 
Immunodeficiency Virus (HIV) (5, 6). Effective STI case management and treatment are 
essential in a country like South Africa where a large proportion of new HIV cases are thought 
to be attributable to other curable STIs (7). Historically, limited access to laboratory diagnostic 
services have stood as a barriers to STI testing but developments in rapid point-of-care (POC) 
STI tests have increased the feasibility of on-site STI diagnosis in resource-poor settings (8–
11).  
1.1   STI Management in South Africa 
South Africa currently follows a syndromic management approach to STI control where 
patients are treated based on the symptoms with which they present rather than deferring 
treatment until laboratory tests are available (12). The introduction of syndromic 
management in the early 1990s was followed by a documented decline in STI prevalence in 
the South Africa population, a trend that modelling studies indicate might also be attributable 
to increased condom usage and HIV/Aids mortality (13). Despite the declines in STI 
prevalence, the prevalence of curable bacterial STIs such as CT and NG is higher in South Africa 
(7)  compared to other African countries and global averages (14).  For example, the 
prevalence of chlamydia and gonorrhoea in South African women in 2005 was estimated to 
be 10.1% and 4.4% respectively (7) compared to levels of 3.0% and 0.3% respectively in high-
income countries (14).  
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It has been well established that 60-70% of chlamydial and gonococcal infections in women 
(15), and possibly a similar proportion in men (15), are asymptomatic. Based on this, in a 
country like South Africa where syndromic management is practiced, it is likely that a large 
proportion of asymptomatic curable STIs go untreated. Unrecognized infection puts women 
at an increased risk for long term reproductive health complications (16)  and contributes to 
a continuously high rate of transmission in the population. A study of South African women 
found vaginal discharge, one of the most commonly treated syndromes under syndromic 
management guidelines, to be a poor predictor for STI status and genital tract inflammation 
(17). Another study, in the rural district of Mopani, Limpopo, found 25% of female study 
participants to be positive for chlamydial and/or gonococcal infections, although only 28% of 
the chlamydia positive and 31% of the gonorrhoea positive women reported having 
symptoms (18). These data bring into question the validity of a syndromic approach to STI 
control. 
1.2  STI screening programmes 
Over the last 20 years, STI screening programs have been implemented in developed 
countries as a cost effective method to identify and treat asymptomatic STI cases and 
interrupt the spread of infection through the population (19–21). Screening for CT was first 
introduced in Sweden in 1982, initially targeting women under the age of 30 and then later 
expanding to offer mandatory free CT testing, treatment and contact tracing in anyone with 
a suspected CT infection (22). While the initiation of this program was followed by a 
temporary reduction in CT rates up until the mid 1990s, CT prevalence in Sweden has 
continued to rise since 1995 (23). In a survey conducted by the European Centre for Disease 
Prevention and Control (ECDPC) in 2012, 18 European countries reported having clinical 
guidelines recommending opportunistic STI testing for at least one high risk population group 
including youth, pregnant women, sex-workers, men-who-have-sex-with-men (MSM) and 
migrants (24).  
 
The ECDPC additionally reported that while the majority of European countries have STI case 
management guidelines, England was the only country with an organised opportunistic 
national chlamydia screening program (24). In 2003 the National Chlamydia Screening 
Program (NCSP) was initiated in England targeting all sexually active men and women under 
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the age of 25 (19). While testing coverage has increased dramatically over the past 10 years 
(25), the NCSP has not yet reached the target of 35% screening coverage of 15-24 year olds 
required to achieve a population wide reduction in CT prevalence (26). In the United States 
(US), CT screening of sexually active women under the age of 25 was implemented in 1988 in 
Region X (Alaska, Idaho, Oregon, Washington) and later expanded across the country. While 
this program has been accredited with a reduction in CT prevalence in certain regions, 
nationwide CT rates continue to rise in the US. A registry-based chlamydia screening program 
implemented in the Netherlands found no reduction in CT prevalence after three rounds of 
annual CT screening (27, 28). 
 
While the population effect of STI screening programs is difficult to determine, multiple 
studies have evaluated the impact of STI screening in clinical trial settings (27–29).  
A meta-analysis of randomized control trial (RCT) evidence for the impact of CT screening 
found that while CT screening does reduce the risk of PID in women, the size of the effect is 
difficult to determine due to the low quality of the clinical evidence available (30). Only two 
studies investigating the impact of CT screening on CT prevalence were identified (27, 28, 31).  
A trial investigating the effectiveness of a registry-based chlamydia screening in the 
Netherlands found no reduction in CT prevalence after three rounds of annual CT screening 
(27, 28) while a trial in Peru found a reduced risk of CT and NG infection in sex workers 
targeted by mobile STI clinics (32). All of the STI screening guidelines that have been 
developed focused on chlamydia specifically, and none have called for gonorrhoea screening. 
This reflects the STI disease burden in high-income countries, in which the prevalence of NG 
is negligible compared to the prevalence of CT (14). In South Africa, however, the prevalence 
of NG is almost half the prevalence of CT (7), and there is thus a need for both CT and NG 
screening. 
 
1.3 Mathematical modelling of STI screening 
Due to the lack of empirical evidence on the efficacy of opportunistic STI screening, dynamic 
mathematical modelling has been used to help understand what levels of coverage and 
frequency of screening are required to reduce STIs levels (26, 33, 34). Modelling studies of 
the impact of STI screening in high-income countries have resulted in substantially different 
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conclusions (35). However, very few modelling studies have been conducted to assess the 
potential impact of opportunistic STI screening programmes in developing countries (36–38). 
It is important to evaluate how an intervention such as opportunistic screening might impact 
STI prevalence in a South African context, given the high STI prevalence levels that persist in 
South Africa. This study aims to utilise an agent based stochastic mathematical model to 
evaluate the impact of opportunistic screening on CT and NG in South Africa in addition to the 



























The aim of this study is to estimate the potential impact of opportunistic STI screening 
programs on the incidence and prevalence of Chlamydia Trachomatis and Neisseria 
gonorrhoea in South Africa through the use of dynamic mathematical modelling.  
2.1 Specific Objectives 
 
2.1.1 Objective One: Extension of an existing mathematical model to estimate the impact of 
STI screening of key sub-populations on the prevalence and incidence of and CT and NG in 
South Africa 
Rationale: High rates of asymptomatic STIs in South Africa indicate there is an urgent need 
for a revision of the South African syndromic management policy. Due to the lack of empirical 
data on the impact of STI screening in the South African context, dynamic mathematical 
models calibrated to available STI data can provide insights into the likely population wide 
impact on STI transmission after the introduction of opportunistic screening programs. This 
study will assess the impact of opportunistic STI screening among those at a high risk of STIs 
(adolescents and female-sex-workers) and those who are already being serviced through 
primary health care access points (pregnant women and those in HIV care).    
 
2.1.2 Objective Two: Comparison of the impact of a chlamydia screening program 
estimated by our model to results obtained from other published mathematical models of 
chlamydia screening.  
Rationale: Previous studies have reported substantially different outcomes predicted by 
three published models of opportunistic chlamydia screening, simulating the identical 
hypothetical screening strategy (33, 35), creating uncertainty in how they may be interpreted 
to inform health policy decision making. We will adjust our model to simulate the same 




3.1 Study Design 
This study will make use of dynamic modelling of infectious disease using the C++ coding 
language through the platform Visual Studio. As such, there will be no human subject data 
collection. 
3.2 Overview of the HIV-STI model 
The study will extend an agent-based version of the STI-HIV interaction model, a previously 
developed model of heterosexual HIV and STI transmission in South Africa (39). For each STI, 
assumptions are made regarding probabilities of transmission per act of unprotected sex, 
proportions of cases that become symptomatic and the average duration of infection in the 
absence of treatment, as has been previously described (39). The model has been fitted to 
South African STI prevalence data, and for each STI a set of 100 STI parameter combinations 
has been identified that yield the best model fit to the STI prevalence data. These 100 
parameter combinations will be used in the current analysis, i.e. the model will be run 100 
times in each scenario in order to generate a distribution of model outputs. The distributions 
will be summarized by medians and inter-quartile ranges.  
3.3 Extension of the HIV-STI model 
We shall introduce structural changes to the STI-HIV interaction model so as to accommodate 
the impact of STI screening interventions. We will introduce the components of a hypothetical 
screening intervention while keeping parameters describing transmission and duration of 
infection the same as in the original model. Those individuals belonging to the targeted key 
populations will be eligible to be screened once every year. The mathematical modelling of 
the natural history of chlamydia and gonorrhoea in this model has been described previously 




Figure 1: Figure S2: Multi-State model of the natural history of chlamydia and gonorrhoea  
Updated from the HIV-STI model (39) to include opportunistic STI screening 
 
The models used for CT and NG are identical in structure but different parameters  
are assigned to each, as previously described (39).  In short, infected individuals may develop 
symptoms or remain asymptomatic (Figure 1). Both states may result in temporary immunity 
after spontaneous resolution of infection or after receiving treatment. Symptomatic 
individuals seek treatment at rate υ, which is successful at curing the infection with the 
probability ψ. Asymptomatic individuals will be screened at rate α, which is a product of three 
independent probabilities: 
(1) The probability of attending a health service where screening is available 
(2) The probability of being offered a screening test 
(3) The probability of accepting a screening test 
These parameters will be calculated separately for each key population based on estimates 











υψ( 1 – φ3 )
+ αψ( 1 – φ3)
σ1 + υψφ3
+ αψ( 1 – φ3)
σ3
σ2 + αψφ2





3.4 Estimation of parameters 
Where possible, the health seeking behaviour of different South African populations has been 
calculated from South African national survey data and epidemiological studies on the impact 
and behaviours associated with STI screening. In the cases where there is no current data on 
these behaviours in the South African population, data sources from other countries, where 
opportunistic screening for CT and NG has been implemented, have been considered. Studies 
selected for calibration comprise of observational studies, where investigators have reported 
samples of youths, pregnant women, female sex workers and those in HIV care, in South Africa 










Table 1: Variables of the STI model used for to simulate the natural history of 
Chlamydia and Gonorrhoea 
Symbol Definition 
φ1 Proportion of people who become symptomatic 
φ2 Proportion of people temporarily immune after experiencing resolution of 
an asymptomatic infection after treatment 
φ3 Proportion of people temporarily immune after experiencing resolution of 
a symptomatic infection after treatment  
σ1 Rate at which symptomatic people recover in the absence of treatment 
σ2 Rate at which asymptomatic people recover in the absence of treatment 
σ3 Rate at which immunity wanes 
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4.  Assessment of Objectives 
4.1  STI screening in key subpopulations 
In each scenario, a hypothetical ten-year screening programme is simulated, starting in 2018. 
Symptomatic individuals seek healthcare and are treated as described in the previous model 
(39). Individuals are screened simultaneously for chlamydia and gonorrhoea with a POC test 
assumed to have the same sensitivity as the chlamydia/gonorrhoea GeneXpert (40).  In each 
scenario, we investigate the impact of targeted screening with and without partnership 
notification. The effectiveness of different screening programs will be assessed by comparing 
the cumulative incidence of new STI cases over the 10-year screening program and the 
reduction in STI prevalence after 10 years of screening, relative to a base scenario in which 
no screening takes place.  
Four targeted screening programs are simulated: 
1. Youth screening: Males and females between the ages of 14 and 25 are eligible for annual 
screening. This screening strategy is in line with global Chlamydia screening policies (41, 
42) 
2. antenatal STI screening for CT and NG is for all women at the onset of prenatal care, and 
again in the third trimester for women who are younger than 25 years or at increased risk 
(43). Our model does not simulate the duration of pregnancy but rather occurrence of a 
new birth. Due to this, antenatal screening is simulated as occurring at birth.  
3. Female Sex Worker (FSW) screening:  All FSWs are eligible for annual screening. 
4. HIV Care Screening: HIV positive individuals, above the age of 14 and on ART-Care are 
eligible for annual STI screening. Recent changes in South African guidelines mandate that 
all HIV positive individual should be initiated onto ART treatment regardless of CD4 counts 
(44), therefore theoretically all individuals with a known HIV positive status should be 






4.2 Standardized screening program 
We will adjust our model to simulate the standardised screening program described by 
Kretzschmar et al. (30) in order to compare the predicted impact of a 10-year screening 
chlamydia program to that estimated by the HPA, RIVM and ClaSS models. We will 
additionally assess how differences in model specifications may explain the difference in the 
predictions produced by our model and those previously published. This will include a 
comparison of model characteristics and assumptions regarding CT natural history as well as 
the calculation of measures such as the effective contact rate and Gini coefficient describing 
the heterogeneity in sexual behaviour specified in each model structure.  
5. Ethical Considerations 
 
As there will be no human subject involvement in this study, there is no potential harm to 
human subjects. The primary benefit of this study is to provide evidence for a revision of the 
syndromic management strategies currently implemented in SA and to increase support for 
opportunistic STI screening in order to decrease population wide STI prevalence and 
incidence.   
6. Potential Outcomes 
 
From this study we hope to evaluate the effectiveness of opportunistic STI screening as a 
method of reducing STIs in South Africa and to identify key populations in which STI screening 
may have a population-wide impact. This study aims to provide data to improve sexual health 
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Bacterial sexually transmitted infections (STIs) are a major contributor to the global burden 
of disease, with Chlamydia trachomatis (CT) and Neisseria gonorrhoea (NG) responsible for 
155 million new infections in 2012 (1). CT infection is predominately asymptomatic with 
approximately 70% of cases in women (2, 3) and 40% in men clinically silent (4, 5). NG 
infections are asymptomatic in up to 60% of women (6, 7) and 20-40% of men (4). If 
undiagnosed or untreated, CT and NG can result in serious reproductive problems including 
pelvic inflammatory disease (PID), ectopic pregnancy and infertility in women (8) as well 
urethritis and epididymitis (9) in men. Bacterial STIs during pregnancy are associated with pre-
term delivery and a range of adverse birth outcomes such as low birth weight and post-
partum endometritis (3). CT and NG transmitted perinatally can cause inclusion conjunctivitis, 
pneumonia and in some cases, neonatal death (3). As well as being a significant contributor 
to morbidity in their own right, bacterial STIs have been shown to increase the risk of both 
the transmission and acquisition of Human Immunodeficiency Virus (HIV) (10, 11). Co-
infection with CT and/or NG has also been associated with higher rates of mother-to-child HIV 
transmission (12).  
 
The transmission of CT and NG occurs via direct mucosal contact through vaginal, anal or oral 
sex and perinatally through the birth canal. Due to the largely asymptomatic nature of 
infection and gaps in knowledge regarding the natural history of both STIs, transmission 
probabilities from cross-sectional partnership studies are difficult to determine (13). Young 
age and behavioural factors such as unprotected sex, multiple or new partners and previous 
STIs are associated with an increased risk of incident CT or NG infection (14). A number of 
studies have found high rates of reinfection in those who have already been treated for CT 
and/or NG (15–18).  In a study of adolescent females, 47% of participants had at least one 
recurrent CT infection after treatment (19). Sexual behaviour data combined with CT 
genotyping, indicated that it is likely that 67% of reinfections originated from new partners, 
17% from the same partner, 14% due to treatment failure and 3% persisted without 
treatment (19).  
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Recurrent CT infections are also associated with an increased risk of PID (20), possibly caused 
by immune-mediated inflammation and adhesion formations in the fallopian tubes after 
repeat exposure to CT antigens (21). There is evidence of partial strain-specific immunity after 
both NG (22, 23) and CT (19, 24)  infections although the underlying mechanisms that mediate 
mucosal immune interactions with bacterial STIs are poorly understood. The rise in chlamydia 
infections observed after an initial reduction of chlamydia prevalence following CT control 
programs, has led researchers to hypothesize that early treatment of CT may interrupt the 
natural immunity process (25, 26).  
2. STI screening  
 
Over the last 20 years, many developed countries have implemented CT screening guidelines 
(27–29) aimed at identifying and treating asymptomatic STIs,  interrupting the spread of 
infection and reducing the incidence of long term reproductive tract complications. These 
recommendations have been implemented despite a lack of high quality clinical evidence on 
the optimal frequency and screening strategy required for population wide effectiveness (30).  
Proactive STI screening strategies identify members of the population eligible for screening 
using population registers (31), with individuals being invited to be screened through 
healthcare services or by receiving a  testing kit that may be self-administered and returned 
to the laboratory (32). Alternatively, opportunistic screening is targeted at individuals who 
are attending healthcare services for reasons other than STI testing (31).  
 
Nucleic acid amplification tests (NAATs) are currently considered the gold standard of CT and 
NG screening and diagnostics. NAATs are more sensitive and the majority are more specific 
than previously available diagnostic methods including cell culture, enzyme hybridisation and 
antigen detection (33).  NAATs can be performed on non-invasive samples including urine or 
self-collected vaginal swabs and many commercially available NAATs can identify the 
presence of CT and NG simultaneously (34, 35). In resource poor settings, limited access to 
laboratory diagnostic services have stood as a barriers to STI testing, but developments in 
rapid point-of-care (POC) STI tests have increased the feasibility of on-site STI diagnosis (36, 
37). In order to be cost effective, many laboratories batch test NAATs and as result the time 
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between diagnosis and treatment can range from a few days to weeks, increasing the risk of 
patients not receiving their results. POC tests can significantly reduce the time between 
detection and treatment and would be particularly effective in populations with high STI 
prevalence where limited access to healthcare facilities makes it difficult for patients to return 
for results. 
 
Mathematical modelling indicates that a CT rapid POC test with a 65% sensitivity would lead 
to higher rates of treatment and a lowered incidence of PID compared to laboratory-based 
NAATs with higher sensitivity and reduced patient return rates (38). POC tests for CT and NG 
developed over the past 5 years utilising antigen detection, enzyme hybridisation and various 
immunoassays have displayed high specificities although the majority have performed poor 
sensitivity (39).  However, qualitative real-time polymerase chain reaction tests, such as the 
Cepheid Xpert CT/NG, demonstrated sensitivities of above 97% for detection of CT in 
endocervical, vaginal, and urine samples, with all specificity estimates above 99.4% (35). NG 
detection was equally robust, with a sensitivity 100% for endocervical and vaginal samples, 
sensitivity of 95.6% for urine samples and all estimates of specificity above 99.8% (35).  The 
Xpert CT/NG has a significantly higher per test cost than commercially available NAATs and 
the feasibility of implementing this test in resource poor settings has yet to be determined 
(39–41).  There is a need for simple and inexpensive POC tests that can be delivered in a single 
patient visit.  
3. Clinical Evidence for STI Screening  
 
There are several clinical trials that have evaluated the feasibility and acceptability of a variety 
of CT screening strategies (42–51), although fewer high-quality randomised controlled trials 
(RCTs) have reported the impact of CT screening on PID and CT prevalence and incidence. The 
Chlamydia Screening Intervention (CSI) trial in the Netherlands used a registry-based 
screening strategy where all men and women aged 16-29 listed on the municipal population 
registers were invited to be screened through postal notifications (52). Results from the CSI 
found no reduction in CT prevalence after three rounds of annual CT screening (52)  and based 
on low rates of participation, concluded that register-based CT screening is not cost effective 
at low levels of coverage (53). Ostergaard et al. randomised 17 high schools to either receive 
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CT self-testing kits or utilise existing free STI-testing services at local healthcare facilities (54). 
Only 7.6% of eligible participants in the control group pursued CT testing at healthcare 
facilities,  compared to the 93.4% of students who returned the self- testing kits (54). There 
was a significant reduction in CT prevalence after one year of follow up in girls at schools that 
received the self-testing kit (55). While the impact of these two screening strategies on CT 
prevalence was largely dependent on screening uptake (low in the CSI trial and high in the 
Ostergaard trial), proactive screening studies are not generalizable to the hypothetical impact 
of population-wide opportunistic screening (32).  
 
The Peru PREVEN study, a community randomised trial targeting female sex workers (FSWs) 
and young adults in the general population, employed a multicomponent STI control program 
(56). The intervention comprised of strengthened syndromic management of STIs by 
pharmacies and clinicians in addition to mobile outreach teams targeting FSWs offering STI 
testing and treatment, presumptive periodic treatment for trichomonis vaginalis and condom 
promotion (56). After 3 years of implementation, a significant reduction in STI prevalence was 
observed in FSWs and young women but not in young males (56, 57). Authors noted that the 
discrepancy in the effect of the intervention seen between FSWs and young males may be a 
result of higher healthcare seeking behaviors in women as well as movement of FSWs 
between cities and infrequent use of condoms with non-client partners (57).  A recent meta-
analysis found insufficient clinical evidence to determine the effect of CT screening on 
population wide CT prevalence and incidence and recommended that the Peru PREVEN trial 
be duplicated in order to determine whether the results are generalizable to other 
populations (58). There are currently two on-going large scale trials in Australia (59)  and 
Denmark (60) investigating the impact of opportunistic screening of CT screening on CT 
prevalence and incidence.  
 
Five RCTs (52, 55, 61–63)  have measured the impact of a single round of CT screening on the 
incidence of PID using both register-based (52, 55, 61, 62) and opportunistic (63) enrolment 
methods. Four trials reported reductions in the incidence of PID in women screened for CT 
compared to those not screened (52, 55, 63, 64) and one trial reported that CT screening had 
no effect on the incidence of PID and ectopic pregnancy in women or epididymitis in men 
(65). Meta-analysis of the combined trial data indicated that while CT screening does reduce 
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the risk of PID in women, the size of the effect is difficult to determine due to the low quality 
of the clinical evidence available (58). PID can be caused by a variety of factors other than CT 
infection, a mediator that was not addressed in the majority these trials. Only the Prevention 
of Pelvic Infection (POPI) trial assessed the prevalence of PID and CT infection at baseline and 
identified incident PID cases that resulted from untreated CT infections (63).  This trial 
reported a non-significant 35% reduction in PID in women screened for CT compared to those 
not screened, noting that overall incidence of PID was low (66). The majority of cases of PID 
occurred in women who tested negative for CT at baseline, indicating that a single round of 
CT screening over a period of 12 months did not prevent the majority of PID cases resulting 
from incident CT infections (66). The time taken for a CT infection to ascend to the fallopian 
tubes following endocervical infection, represents a window in which CT screening and 
treatment may prevent immune-mediated tubal pathology (67). The impact of CT screening 
on fertility outcomes is currently unknown, but the results from the POPI trial indicate that 
annual opportunistic screening might fail to reduce PID outcomes in those at high risk for a 
repeat infection.  
 
Despite the strong associations between bacterial STIs and adverse birth outcomes, there is 
currently no high quality clinical trial evidence on the impact of antenatal STI screening 
programs. Antenatal screening and treatment for bacterial vaginosis (BV), high vaginal pH and 
abnormal vaginal flora has been shown to reduce birth adverse outcomes (68). Recent clinical 
trials have demonstrated antenatal STI screening to be feasible and acceptable in both high 
(69) and low-resource settings (48, 49). A pilot study in Papua New Guinea found POC testing 
for CT, NG and BV during routine antenatal visits to be feasible (70), prompting a cluster 
randomised trial investigating the efficacy, cost-effectiveness and health system 
requirements for POC antenatal STI testing which is currently on-going (71).  
4. Chlamydia screening globally  
 
CT screening was first introduced in Sweden in 1982, targeting women under the age of 30 
attending family planning clinics as well as male partners of those infected (72). A change in 
legislation in 1988 introduced mandatory free CT testing, treatment and contact tracing of 
anyone with a suspected CT infection, as well as mandatory notification of any confirmed CT 
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cases (72). The widespread introduction of these screening activities, in combination with 
educational campaigns and the provision of youth friendly STI clinics, are thought to have 
contributed to the decline in Sweden’s CT notifications up until the mid 1990s (73). However, 
the decline in CT notifications in Sweden was preceded by nationwide HIV prevention 
campaigns and resultant changes in sexual behaviours, which may have contributed to 
decreased STI rates (74) as observed in other countries where no CT control interventions 
were in place (75). Despite continued screening services, CT notifications in Sweden have 
steadily risen since 1995 (30). While the increase in CT notifications in Sweden may be partly 
attributable to increased sensitivity of laboratory diagnostics and increased screening in men, 
CT rates in both men and women aged 15-19 began to rise prior to the introduction of NAATs 
and were observed in laboratories that had not yet implemented more sensitive diagnostics 
(76).  
 
In a survey conducted by the European Centre for Disease Control (ECDC) in 2012, 18 
European countries reported having clinical guidelines recommending opportunistic STI 
testing in asymptomatic individuals in at least one population group including youth, pregnant 
women, sex-workers, men-who-have-sex-with-men (MSM) and migrants (77).  However, 
implementation of these guidelines has not been successful, with only 5 countries reporting 
that opportunistic STI testing was actually practiced (77). Between 2008 and 2011 a registry-
based chlamydia screening program was implemented in the Netherlands targeting all men 
and women aged 16-29 listed on the municipal population register but was halted after RCT 
findings that annual register based screening was not cost-effective in this population due to 
low participation rates (52, 53).  
 
The ECDC additionally reported that while the majority of European countries have STI case 
management guidelines, England was the only country with an organised opportunistic 
national chlamydia screening program (77). In 2003 the National Chlamydia Screening 
Program (NCSP) was initiated in England, recommending annual screening for all sexually 
active men and women under the age of 25, screening after change of a sexual partner and 
rescreening 3 months after a positive test in addition to partner notification (27). While 
testing coverage has increased dramatically over the past 10 years (78), the NCSP has not yet 
reached the target of 35% screening coverage of 15-24 year olds required to achieve a 
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population wide reduction in CT prevalence (79). In 2015, 32% of women and 13% of males 
in this age group were testing for CT in England (78). While CT screening in the UK is primarily 
utilised at specialist and non-specialist sexual health centres, the NCSP also offers online 
services through which home based CT testing kits can be freely accessed (80). The usage of 
internet testing has risen considerably in the UK, particularly in young males, a population in 
which CT screening coverage is low (81). Since nationwide implementation of the NCSP, CT 
diagnoses in the UK have risen consistently (78). This is partially due to increased screening 
coverage and higher diagnostic sensitivity but most likely a reflection of on-going unsafe 
sexual behaviours in this population (78).  
 
In the United States (US), CT screening of all sexually active women under the age of 25 
attending family planning clinics was implemented in 1988 in Region X (Alaska, Idaho, Oregon, 
Washington) (82). For the first 9 years of this program, while CT notifications in women rose 
nationwide (83, 84) , CT notifications decreased by more than 60% in women aged 15-24 
attending family planning clinics in region X (85). Over this time period, decreases in CT 
positivity were also observed in other regions of the US where screening was being broadly 
implemented (86, 87). However, from 1997 to 2004 there was a 46% increases in CT positivity 
in women attending family planning clinics in Region X (85).  This increase in CT infections 
could not be accounted for by increased sensitivity of laboratory diagnostics (88) and some 
have hypothesised that widespread early treatment interrupting the development of natural 
immunity to CT may have contributed to an increased number of susceptible individuals in 
the population (88). CT prevalence continues to rise in the US with 1.5 million cases, the 
highest number of annual cases, reported in 2015 (89).   
5. Gonorrhoea Screening Globally 
 
Due to a hypothesized combination of changing sexual behaviours and the introduction of 
hormonal contraceptives (90) NG rates in US increased rapidly from the 1960s reaching a peak 
in the mid 1970s (91). The introduction of the national gonorrhea control program resulted 
in a 74% decline in the rate of NG notifications between 1975 and 1997 (91) with NG rates 
reaching a historical low in 2009 (92). Since then, NG rates have risen consistently (92) and 
NG resistance to first-line antibiotics is  becoming a global concern (93, 94).While CT and NG 
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are the two most frequently reported bacterial STIs, the global prevalence of NG is only a 
tenth of that of CT (95) and the majority of STI screening programs have therefore focused on 
CT screening. The WHO recommends discontinuing the use of a given first line antibiotic when 
resistance has been identified in more than 5% of circulating NG strains(96). As of 2010, there 
is only a single first line antibiotic combination that is effective above this threshold (97).Due 
to the overall low prevalence of NG and the threat of increasing antimicrobial resistance, 
opportunistic screening for gonorrhoea is not recommended unless clinically indicated (98). 
There are currently no formalised NG screening programs but many countries recommend 
NG screening in high risk population groups such as MSM (98, 99). Extra genital screening 
(pharyngeal and rectal) for both NG and CT is recommended in this population with studies 
reporting that the majority of asymptomatic STI cases would be missed using urethral only 
screening (100, 101). 
6. Use of mathematical models to evaluate the impact of STI Screening 
 
Due to the lack of empirical evidence on the efficacy of opportunistic STI screening in both 
clinical and population intervention settings, dynamic mathematical modelling has been used 
to help understand the levels of coverage and frequency of screening required to reduce STIs 
levels (79, 102, 103). Modelling the impact of STI screening has been achieved using both 
deterministic and stochastic frameworks. Parameters such as the duration of infection, 
treatment efficacy and rates of health care utilisation are generally based on estimates from 
nationally representative surveys and clinical studies. The transmission dynamics of STI 
models are highly dependent on the specified mixing patterns through which members in the 
hypothetical population interact and models differ in the assumptions of age- and sex-
specified sexual  behaviours (104). Deterministic, population-based models simulate 
interactions between homogenous compartments of individuals within the population and 
therefore represent the average behaviour of a system. Stochastic, individual-based models 
simulate individual interactions based on randomly assigned characteristics sampled from 
specified probability distributions and randomly simulated times to events (events might 
include, for example, formation of a new sexual partnership, or acquisition of an STI).  In terms 
of modelling STIs such as CT and NG, stochastic simulations do a better job of capturing the 
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dynamics of sexual partnerships (105) although they require greater computational power to 
run.  
 
Kretzschmar et al. compared three different stochastic individual-based models of CT 
screening strategies that reported substantially different outcomes (106). The first model, 
developed by Kretzschmar et al., compared the impact of condom usage, contact tracing and 
screening for CT and NG on population wide prevalence of CT and NG (107). The model 
predicted that all three prevention strategies were more effective in reducing NG prevalence 
than CT prevalence and recommended that contact tracing and treatment of at least 50% of 
partners would be required for a sustained reduction in CT prevalence (107). The second 
model, developed by Turner et al., identified ideal levels of screening coverage for the 
National Chlamydia Screening Program in the UK (108). This model indicated that a screening 
coverage of 35% would be required for a population wide decrease in CT prevalence, a target 
which has been adopted by the NCSP (109).  A similar model was developed by the UK 
Chlamydia Screening Studies (ClaSS) to evaluate register-based screening with home collected 
CT testing kits (110).  
 
While the Turner model estimated a 50% reduction in chlamydia prevalence after 10 years of 
annual screening with a 10% annual screening uptake (79), the ClaSS model estimated that a 
35% annual screening uptake in all sexual activity groups would only result in a 10% reduction 
in CT prevalence over  the same period of time (111). A comparison of the Turner, 
Kretzschmar and ClaSS models, simulating the identical hypothetical CT screening strategy, 
predicted a 85%, 25%  and 5% reduction in CT prevalence in women respectively (106). These 
disparities arose as a result of different assumptions about the sexual partnership dynamics 
and the parameters regarding the natural history of chlamydia (106).  
 
In lieu of more reliable data collection methods, self-reported national surveys often 
constitute the only empirical data on population wide sexual behaviours. In comparison to a 
survey of sexual behaviours in the UK, as well as the Kretzschmar and ClaSS models, the 
Turner model estimated significantly higher rates of sexual contacts in young adults (112). 
This may have resulted in an unrealistically high prevalence of CT in the population eligible to 
be screened, explaining the larger impact of the same screening intervention observed in this 
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model in comparison to the others (106, 112). In the same comparison, the ClaSS model was 
shown to overestimate the proportion of single members of the population, resulting in a 
reduced effect of the intervention, as screening those in partnerships in the population is 
more effective in reducing CT transmission (112). Overall, the Kretzschmar model was found 
to best describe the dynamics of the CT transmission, sexual partnerships and the distribution 
of CT in the population (112, 113), despite it being the earliest and least complex of the 
models compared.  
 
One of the caveats of stochastic individual-based models is that the inclusion of many 
complex parameters, in the absence of reliable empirical data, can lead to difficulties in 
interpretation of the results (114). Althaus et al. developed a novel stochastic individual-
based framework,  creating three different models with simplifying assumptions that may be 
easily compared and  adjusted (115). A comparison of the impact of two different partner 
notification strategies on CT screening effectiveness demonstrated that notifying current or 
most recent sexual partners has a larger impact on reducing population wide CT transmission 
compared to notifying all partners within a defined look-back period (115).  
 
The concept of core sexual activity groups, now adopted by most sexual infection 
transmission models, was introduced by Yorke et al. in 1978 in mathematical model describing 
the natural history and transmission dynamics of NG (116). More recent mathematical models 
of NG have focused on the transmission dynamics of antibiotic resistance in NG networks. The 
use of risks structured “susceptible-infectious-susceptible’ model revealed that a significant 
reduction in NG infection can only be achieved by screening and treating core sexual groups 
although this strategy increases the spread of antimicrobial resistance (117). A deterministic 
model created by Xiridou et al. predicted that in MSM, a short term reduction of  NG 
prevalence as a result of increased treatment may be overshadowed by increased 
antimicrobial resistance and a resultant increased prevalence in the long term (118). A recent 
modelling study identified higher rates of treatment, as opposed to higher numbers of 
partners, as the main reason for the more rapid emergence of antibiotic-resistant NG in MSM 
when compared to heterosexuals (119). These modelling studies highlight the necessity to 
consider the spread of NG resistance when developing public health recommendations for 
NG screening (120). With the exception of the Kretzschmar model (107), there have been no 
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recent mathematical models evaluating the population wide impact of a hypothetical NG 
screening strategy.  
 
Few modelling studies have been conducted to assess the potential impact of opportunistic 
STI screening programmes in developing countries (121–123). A deterministic model 
evaluating the impact of periodic presumptive treatment (PPT) found that a PPT coverage 
above 30% could significantly reduce the prevalence of CT and NG in South African FSWs 
(121).  Another study assessed the cost effectiveness of rapid POC testing for antenatal 
syphilis screening in Tanzania (123). A stochastic model was used to compare the time-to-
detection of the emergence of microbial resistance using POC molecular testing and culture 
methods in resource limited settings (37). When modelling the impact of public health 
interventions on CT and NG transmission, there are still concerns about the validity of 
assumptions of treatment rates estimated from clinical trials that may not be generalizable 
to the greater population (106) and empirical data from high quality RCTs of screening 
programs are needed to better inform health policy decisions.  
7. STI Management in South Africa 
 
South Africa follows a syndromic management approach to STI control where patients are 
treated based on the symptoms with which they present rather than deferring treatment until 
laboratory tests are available (124). The introduction of syndromic management in the early 
1990s was followed by a documented decline in STI prevalence in the South Africa population, 
a trend that modelling studies indicate might also be attributable to increased condom usage 
and HIV/Aids mortality (125). Despite the declines in STI prevalence, the prevalence of curable 
bacterial STIs such as CT and NG is higher in South Africa (41, 126)  compared to other African 
countries and global averages (1). A study of South African women found vaginal discharge, 
one of the most commonly treated syndromes under syndromic management guidelines, to 
be a poor predictor for STI status and genital tract inflammation (127). Another study, in the 
rural district of Mopani, Limpopo, found 25% of female study participants to be positive for 
chlamydial and/or gonococcal infections, although only 28% of the chlamydia positive and 
31% of the gonorrhoea positive women reported having symptoms (128). The presumably 
high levels of asymptomatic STIs in the South African population bring into question the 
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adequacy of a syndromic approach to STI control, yet the feasibility of an STI screening 
program in this country has yet to be determined.  
8. STI epidemiology and targeted screening strategies 
8.1  Adolescents and young adults 
 
In the USA, 14-25 year olds account for 65% of CT infections and 53% of NG infections (89) 
making them disproportionately affected by STIs compared to other age groups. High rates of 
bacterial STIs within this age group have directed STI screening strategies in the US, UK, 
Sweden and Australia. Barriers to accessing healthcare, multiple concurrent sexual partners 
and limited knowledge of sexual health contribute to increased risk of STIs during 
adolescence(129). Additionally, cervical ectopy during adolescence may place young women 
an increased risk of bacterial STI acquisition (130). In the US, annual routine screening for CT 
and NG is recommended for all sexually active females under the age of 25, young men who 
have sex with men and sexually active young males in settings with a high STI prevalence 
(correctional facilitates and STD clinics) (99).  
 
The burden of bacterial STIs is lower in the UK with 368.7 cases of CT and 75.8 cases of NG 
reported per 100,000 population in 2015 in comparison to the 456,1 cases of CT and 110,7 
cases of NG reported per 100,000 population in the US in  2014 (87) (131). Similar to the US, 
CT diagnoses are highest in female adolescents and NG diagnoses are concentrated in high 
risk groups such as MSM (78). In the UK, annual CT screening is recommended for all sexually 
active men and women under the age of 25 or after change of sexual partners (78). 
Opportunistic screening for gonorrhoea is not recommended unless clinically indicated  (98).  
 
There is no empirical data on the population wide epidemiology of bacterial STIs in South 
Africa and clinical studies employing laboratory testing of STIs report varying levels of STI 
prevalence in different regions and sentinel populations (132). The prevalence of chlamydia 
and gonorrhoea in South African women in 2005 was estimated to be 10.1% and 4.4% 
respectively (126) compared to levels of 3.0% and 0.3% respectively in high-income countries 
(1). Consistent with global trends, CT rates in South African adolescent females are generally 
higher than their male counterparts (133, 134). At the initiation of an HIV RCT in South African 
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adolescents aged 15-19, 23.1% and 8.2% of females and males tested positive for CT while 
10.6% and 1.8% of females and males tested positive for NG (134). Another study assessing 
youth-directed HIV prevention services reported CT prevalence to be 9.1% and 10.8% in 
women aged 15-19 and 20-24, while CT prevalence in men of the same ages was 3.5% and 
10.1% (133). In the same study, NG prevalence in was 3.5% in both female age groups and 
1.1% and 3.2% for men aged 15-19 and 20-24, respectively (133). A study in the peri-urban 
township of Masiphumelele reported unusually high rates of asymptomatic STIs in female 
adolescents, with 41% and 20% of the girls testing positive for CT and NG at screening in the 
absence of symptoms (Barnabas et al. unpublished). These data indicate that bacterial STIs 
are prevalent in South African adolescents, possibly to a greater extent than their global 
counterparts.  
 
8.2  Female Sex Workers  
 
Globally, female sex-workers (FSWs) have been identified  as a key target group for STI 
screening studies (135–138) and in South Africa have been identified as a key population at a 
high risk for both HIV (139) and other STIs (140). Global studies in both high- (141, 142) and 
low-income countries have reported FSWs to have higher bacterial STI prevalence compared 
to the sexually active females in the general population. A study of FSWs in Johannesburg, 
South Africa revealed a CT prevalence of 11% and an NG prevalence of 35% in 1999 (143).  
The same population was retested two years later and while NG prevalence had decreased 
by 10%, CT prevalence had risen by 6% (143). Similar to other high risk groups, clinical studies 
reporting bacterial STI prevalence in FSWs vary (143–145), although they consistently report 
higher NG rates than the estimated average among female South Africans (126). STI screening 
in FSWs has been shown to be acceptable and feasible in other low-income countries and 
mathematical modelling demonstrated that POC testing for CT and NG in South African FSWs 
would have averted 18 000 additional CT and/or NG infections compared to the current 
syndromic management approach (122). The recent introduction of pre-exposure prophylaxis 
for FSWs in SA provides the opportunity to build onto existing infrastructure to reach a 
population at high risk for both HIV and STIs concurrently.  
8.3  Antenatal Screening  
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In addition to targeting adolescents and FSWs, STI screening can be employed to at-risk 
populations who are already accessing health care services. The majority of developed 
countries have policies for antenatal CT and NG screening, although implementation varies 
(146). Southern Africa has a high prevalence of curable STIs among pregnant women in 
comparison to other middle- to  low-income countries (147). Clinical trials have reported high 
levels of undiagnosed and untreated curable STIs in pregnant women in South Africa (148, 
149), indicating that a large majority of curable STIs in South African pregnant women may be 
undetected by current syndromic management practices. South African antenatal screening 
policies currently include laboratory diagnosis of only HIV and syphilis (124). Universal 
antenatal screening, which refers to screening pregnant women for CT and NG regardless of 
symptoms or risk factors, has been shown to be acceptable and feasible in low-income setting 
where women are already attending antenatal clinics for routine checkups (41, 49, 150, 151). 
Since the introduction of universal antenatal syphilis screening in the early 1990s, national 
antenatal syphilis levels have decreased from 11% in 1998 to 2.8% in 2001 (152) although this 
trend may have been impacted by the introduction of syndromic management and changing 
sexual behaviours (125). Since the majority of pregnant South Africans access antenatal 
health services at least once before giving birth (153), antenatal screening provides a potential 
STI screening service entry point.  
8.4  HIV Care Screening 
 
Reports of high levels of asymptomatic CT and NG cases at North American HIV clinics resulted 
in the Centre for Disease Control (CDC) recommending at-least annual CT and NG screening 
for PLWHA (154). North American studies report high levels of STIs and increased high risk 
behaviours for STI acquisition in MSM on antiretroviral (ART) treatment (155). It is unclear 
whether these risk behaviours are specific to MSM, or extend to the general population on 
ARTs. Result from an HIV cohort in Kenya reported low levels of sexual risk behaviour and 
bacterial STI prevalence (1-2%) in PLWHA (156). A systematic review reported lower levels of 
unprotected sex and STIs in those on ARVs compared to those not on ARVs (157). While the 
prevalence of bacterial STIs in South African PLWHA is currently unknown, a study of PLWHA 
offered opportunistic STI screening at an HIV clinic in Johannesburg reported CT and NG levels 
of 4.4% and 2% respectively in men as well as 6.4% and 2.2% in women (158).  
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There is evidence that CT and/or NG infection may increases genital viral load in HIV positive 
people on antiretroviral (ARV) treatment  and therefore increase the risk of HIV transmission 
from people living with HIV (PLWHA) (159).  In the absence of any other intervention, 
detecting and treating STIs in PLWHA has been estimated to be responsible for an 
approximately 27% reduction in HIV transmission (160). While ART treatment significantly 
reduces the risk of HIV transmission (161), PLWHA may represent a population with a high 
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Background: A large proportion of chlamydial and gonococcal infections are asymptomatic. 
In lower- and middle-income countries like South Africa, where syndromic management is 
practiced, it is likely that a large proportion of curable sexually transmitted diseases (STIs) go 
untreated, as opportunistic screening for asymptomatic STIs is rarely conducted. Due to the 
lack of empirical data on the effectiveness of STI screening programs, dynamic mathematical 
modelling has been used to assess the impact of screening, although most previous modelling 
studies have focused on high-income settings.  
Methods: Here we utilize dynamic mathematical modelling to evaluate the potential impact 
of opportunistic STI screening programs on the incidence and prevalence of Chlamydia 
trachomatis and Neisseria gonorrhoea in South Africa. We extended an existing agent-based 
model of heterosexual HIV and STI transmission in South Africa to investigate the impact of 
targeted screening strategies directed at high risk groups including youth, female sex workers, 
pregnant women and patients in HIV care. Additionally, we compared the modelled impact 
of a standardized screening program to results obtained from other published mathematical 
models of chlamydia screening. 
Results: All four screening strategies resulted in reductions in general and key population STI 
transmission. Differences between models could be attributed to differences in the modelled 
heterogeneity in sexual behaviour as well as differences in assumptions about immunity 
following chlamydia recovery.  
Conclusions: Opportunistic STI screening of youth and ART patients were shown to be most 
effective and represent viable interventions for reducing STI transmission in the South African 
population. 
 
Keywords: STI screening; mathematical model; chlamydia; gonorrhoea; South Africa  
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Introduction 
Sexually transmitted infections (STIs) are a major contributor to the global burden of disease, 
especially in developing countries with limited resources for diagnosis and treatment. 
Globally, bacterial STIs such as Chlamydia trachomatis and Neisseria gonorrhoea were 
responsible for 155 million new infections in 2012 (1). South Africa currently follows a 
syndromic management approach to STI control where patients are treated based on the 
symptoms with which they present rather than deferring treatment until laboratory tests are 
available (2). Despite documented declines in STI prevalence (3), the prevalence of curable 
bacterial STIs such as chlamydia and gonorrhoea remains high in South Africa (4)  compared 
to other African countries and global averages (1).  
 
It has been established that 60-70% of chlamydial and gonococcal infections in women (5), 
and possibly a similar proportion in men (6), are asymptomatic. If undiagnosed or untreated, 
chlamydia and gonorrhoea can result in serious reproductive problems including pelvic 
inflammatory disease (PID), ectopic pregnancy and infertility in women (7) as well urethritis 
and epididymitis (8) in men. Reports from clinical studies indicate a high burden of 
asymptomatic STIs in South African women (9, 10), bringing into question the adequacy of a 
syndromic approach to STI control.  
 
Opportunistic STI screening programs have been implemented in developed countries to 
identify and treat asymptomatic STI cases and interrupt the spread of infection through the 
population (11–13). Despite this, rates of curable bacterial STIs have risen consistently in the 
United States (US), United Kingdom (UK) and Sweden where STI screening programs have 
been widely established (14).  This has raised questions about the quality, or absence, of the 
clinical evidence currently informing STI screening strategies (14). Due to the lack of empirical 
data on the effectiveness of opportunistic STI screening, dynamic mathematical modelling has 
been used to help understand the levels of coverage and frequency of screening required to 
reduce STIs levels (15–17). However, very few modelling studies have been conducted to 
assess the potential impact of opportunistic STI screening programmes in developing 
countries (18–20).  
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Effective STI case management and treatment are essential in a country like South Africa 
where a large proportion of new Human Immunodeficiency Virus (HIV) cases are thought to 
be attributable to other curable STIs (4). Historically, limited access to laboratory diagnostic 
services has stood as a barrier to STI testing but recent developments in rapid point-of-care 
(POC) STI tests have increased the feasibility of on-site STI diagnosis in resource-poor settings 
(21, 22). This study uses a previously developed agent-based model of STIs in South Africa to 
estimate the effectiveness and efficiency of opportunistic STI screening in a South African 
setting. We investigate the impact of targeted screening strategies directed at high risk groups 
including youth, female sex workers, pregnant women and those in HIV care. Additionally, we 
compare the modelled impact of a standardized screening program to results obtained from 
































Materials and Methods  
We extended a previously developed model of heterosexual HIV and STI transmission in South 
Africa (23). MicroCOSM (Microsimulation for the Control of South African Morbidity and 
Mortality) is an agent based model simulating the behaviour and disease profile of a 
representative sample of South Africans; the initial population size in 1985, at the start of the 
simulation is 20 000, and the model is projected to 2028. A detailed description of the sexual 
behaviour parameterization can be found elsewhere (23). Briefly, the population is stratified 
by sexual risk behaviour. High risk individuals have a propensity for concurrency and engaging 
in sex work and low risk individuals engage only in monogamous relationships. Both short-
term (non-cohabitating) and long-term (cohabiting) relationships are simulated. High risk 
individuals may have a maximum of two concurrent partners.  
 
We have introduced the components of a hypothetical screening intervention while keeping 
parameters describing the transmission and duration of infection the same as in the original 
model (23).  For the purpose of this study, only chlamydia, gonorrhoea and HIV transmission 
are simulated. Assumptions are made regarding probabilities of transmission per act of 
unprotected sex, proportions of cases that become symptomatic and the average duration of 
infection in the absence of treatment, as has been previously described (23). The model has 
been fitted to South African STI prevalence data, and for each STI a set of 100 parameter 
combinations has been identified that yield the best model fit to South African STI prevalence 
data (Tables S2 and S3).  
 
STI Screening 
In each scenario, a hypothetical ten-year screening programme is simulated, starting in 2018. 
Symptomatic individuals seek healthcare and are treated as described in the previous model 
(23). A description of the screening and testing strategies is detailed in the appendix. 
Individuals are screened simultaneously for chlamydia and gonorrhoea with a POC test 
assumed to have the same sensitivity as the chlamydia/gonorrhoea GeneXpert (24).  In each 
scenario, we investigate the impact of targeted screening with and without partner 
notification. In partner notification scenarios, if screening produces a positive result, both 
primary and secondary (when applicable) partners are screened with a probability of 50%. 
These estimates are based on studies implementing standard patient referral whereby index 
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cases are given the responsibility of notifying partners (Table S5, Appendix).  Partners are 
successfully treated with the same probability as index cases. The effectiveness of different 
screening programs was assessed by comparing the cumulative incidence of new STI cases 
over the 10-year screening program and the reduction in STI prevalence after 10 years of 
screening, relative to a base scenario in which no screening takes place.  
 
Targeted screening strategies 
In the case of antenatal screening, a single screening probability was applied to all pregnant 
women based on the current rates of antenatal syphilis screening in South Africa (25). The 
other screening strategies, for which the probability of screening is unknown, are as follows: 
Youth screening: Males and females between the ages of 15 and 24 are eligible for annual 
screening.  
Female Sex Worker (FSW) screening:  All FSWs are eligible for annual screening. 
HIV care screening: HIV positive individuals, above the age of 14 and either on ART or in the 
symptomatic stages of HIV disease (WHO stage III or IV) are eligible for annual STI screening.  
The annual rate of STI screening in these populations was calculated as the product of the 
probability of health care utilisation, STI screening acceptability and screening coverage (the 
probability of being offered an STI test). STI screening parameters were specified separately 





















Table 1: Model parameters 
Parameter Females Males       Source  
Probability of screening in populations with known screening rates 
ANC  0.71 N/A Literature (25) 
Assumed rate of screening in populations for which screening rates are unknown 
Screening coverage 0.80 0.80  
Annual Health Care Utilisation rate 
    Adolescents  0.48 0.32 GHS (26) 
    FSWS 0.50 N/A Literature (27–31) 
    ART patients 0.90 0.90 Literature (32, 33) 
Screening acceptability    
    Adolescents 0.60 0.60 Literature (34–42) 
    FSWS 0.80 N/A Literature (29, 43, 44) 
    HIV care 1.00 1.00 Literature (32)* 
Annual screening rate    
Adolescents 0.23 0.15 
N/A 
0.72 
The total screening probability was calculated as a 
combination of heath care utilisation, screening 





Partner Notification**    
Proportion of partners screened 0.50 0.50 Literature (45–52) 
ANC = antenatal care, FSW = female sex worker, GHS = General Household Survey  
* Based on reports that that the majority of South Africans on ART receive laboratory monitoring at least 
annually (32) 
** Only applicable in scenarios where partner notification is implemented  
 
Standardized screening program 
Previous studies have compared three published models of opportunistic chlamydia 
screening, simulating the identical hypothetical screening strategy in European settings (16, 
53). We adjusted our model in order to simulate the same screening strategy and compared 
the outcomes to the above-mentioned studies. In order to be comparable, the following 
adjustments were made: 16-24 year olds were screened with an annual probability of 35% 
and partner notification resulted in 45% of partners successfully screened and treated (16). 
This was for done for men and women simultaneously and women alone. Assumptions 
regarding test sensitivity and treatment success of index cases were consistent with our 
original model. We calculated the Gini coefficient, a measure of the distribution of chlamydia 
infections among individuals with different levels of sexual activity (53).  A Gini coefficient of 
0 represents a situation where the distribution of chlamydia infections is equal across all 
sexual behaviour groups. A Gini coefficient of 1 represents a situation of maximum inequality 
where chlamydia infections occur only in the group with the highest rate of sexual contacts. 
We also assessed how model characteristics and assumptions regarding chlamydia natural 




Population level impact of targeted STI screening 
Figure 1 illustrates the predicted change in population level chlamydia and gonorrhoea 
incidence and prevalence after different screening strategies, relative to the base scenario. 
Tables S11-13 detail the estimated population chlamydia and gonorrhoea incidence and 
prevalence over the period of the screening program. For both chlamydia and gonorrhoea 
incidence, HIV care screening resulted in the largest decrease in cumulative incidence over 
the 10 years of the screening period, followed by youth, ANC and FSW screening (Table S11). 
The same trend was seen for population wide chlamydia prevalence in both males and 
females, with all screening strategies resulting in significant reductions relative to the base 
scenario (Figure 1, Tables S11 and S12). Significant reductions in population wide gonorrhoea 
prevalence were only seen for HIV care screening (Figure 1). Partner notification resulted in 
significantly fewer incident and prevalent cases of chlamydia for both men and women for all 
screening scenarios in comparison to screening without partner notification (Figure 1). Across 
all scenarios, partner notification did not significantly reduce the number of incident or 
prevalent cases of gonorrhoea. Screening FSWs was the most efficient screening strategy 
resulting in significantly more STI cases averted per screening test than any of the other 
screening strategies (Table 2).  
 
Key population impact of targeted STI screening 
Estimates of chlamydia and gonorrhoea prevalence in key populations after different STI 
screening scenarios are summarised in Table 3. Chlamydia prevalence in women was highest 
in sex workers, lower among youth and pregnant women, and lowest in ART patients, but 
chlamydia prevalence in men was higher among ART patients than among youth. Similar 
prevalence differentials were estimated in the case of gonorrhoea. Significant reductions in 
chlamydia prevalence were predicted in ART patients, youth, pregnant women and FSWs 
after respective targeted screening strategies (Tables 3 and S13). Significant reductions in 
gonorrhoea prevalence after targeted screening were predicted in all key populations with 
the exception of male youth and pregnant women (Tables 3 and S13). Partner notification 
resulted in significantly fewer prevalent cases of chlamydia in all key populations but had no 
impact on the reduction in gonorrhoea prevalence in comparison to targeted screening 




Sensitivity analysis correlating the reduction in chlamydia and gonorrhoea incidence and 
prevalence with the 100 best fitting parameter combinations revealed that the probability of 
chlamydia transmission per sex act was positively correlated with the reduction in chlamydia 
incidence and prevalence due to screening (Table S9). Additionally, the duration of 
asymptomatic chlamydial infection and the duration of chlamydial immunity were negatively 
associated with the reduction in chlamydia incidence and prevalence (Table S9). The same 
relationships were not observed between gonorrhoea transmission factors and reductions in 
gonorrhoea incidence and prevalence (Table S10).  
 
Standardized screening program  
The predicted chlamydia prevalence prior to screening, annual number of partners and 
effective contact rate for women and men stratified by age is summarised in Table S14. The 
model characteristics and chlamydia natural history parameters of three previously published 
individual-based stochastic models of chlamydia transmission and the model used in this 
study (the MicroCOSM model) are summarised in tables S15 and S16.  The RIVM, ClaSS and 
HPA models predicted a pre-screening chlamydia prevalence of 3.2%, 2.6%, 2.8% in women 
and 2.9%, 3.1%, 3.7% in men respectively (16). In our model, pre-screening chlamydia 
prevalence in 16- 44 year olds was substantially higher, at 10.16% (95% CI: 9.94-10.39%) for 
females and 7.40% (95% CI: 7.18-7.16%) for males. The MicroCOSM model estimated the 
impact of the standardized chlamydia screening programme to be similar to that estimated 
by the RIVM model, but substantially less than that estimated by the HPA model and 
substantially more than that estimated by the ClaSS model (Figure 2). The Gini coefficient 
calculated for the MicroCOSM model (0,37) was similar to that calculated from empirical data 
collected in the Natsal 2000 population-based survey in Britain (0,38) (53), but was slightly 
higher than that estimated for the HPA model (0,32) and lower than that estimated for the 





































Figure 1: Comparison of estimated population level effect of youth, female sex-worker (FSW), 
antenatal care (ANC) and HIV care targeted STI screenings strategies. Both targeted screening 
and targeted screening in combination with partnership notification (PN) are shown. Bars 
represent mean reductions in the cumulative number of new chlamydia (CT) and gonorrhoea 
(NG) cases (A+ B) or CT and NG prevalence (C - F) 10 years after the implementation of 
targeted STI screening programs (errors bars represent 95% confidence intervals). Lower 
limits of the 95% CI are not shown if they extend past zero. The means and 95% CIs are 
calculated from the range of model outputs generated when the 100 best-fitting parameter 
combinations are entered into each model. The hypothetical implementation of STI screening 
programs is simulated as starting in 2018, and the reduction in incidence and prevalence is 
calculated relative to the level that would be expected in the absence of any screening 






































































































































Youth FSW ANC HIV Care
(A) Population CT Incidence (B) Population NG Incidence
(C) CT prevalence females (15 - 49)
(E) NG prevalence females (15 - 49)
(D) CT prevalence males (15 - 49) 
(F) NG prevalence males (15 - 49)
Targeted screening Targeted screening + partner notification
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Table 2: Estimated number of new STI cases averted (in the general population) per 100 
individual STI tests *  
Screening strategy Chlamydia Gonorrhoea 
Adolescent  5.7 (5.1-6.3) 5.2 (3.1-7.2) 
Adolescent PN 6.9 (6.2-7.5) 5.9 (4-7.8) 
FSW 45 (13-78) 248 (140-357) 
ANC 5.5 (4-7) 8.2 (1.5-14.9) 
ANC PN 7.5 (6-9) 6.5 (1.1-11.9) 
HIV Care 5.2 (4.8-5.6) 5.5 (4.3-6.7) 
HIV Care PN 6.3 (5.8-6.7) 5.8 (4.5-7.1) 
*Number of STI cases averted per single dual screening test was calculated as the cumulative reduction in incident STI cases divided by the 
total number of screening tests over the 10-year screening period.   
The means and 95% CIs are calculated from the range of model outputs generated when the 100 best-fitting parameter combinations are 
entered into each model. 
ANC = antenatal care, ART = antiretroviral treatment, FSW = female sex worker, PN = partner notification 
 
Table 3: Estimated STI prevalence in key populations in 2028, after the implementation of a 
10-year targeted screening program 
 Chlamydia Gonorrhoea 
Scenario Females Males Females Males 
Prevalence in the general population (aged 15 to 49 years) 
Base scenario* 8.87 (8.69-9.05) 6.56 (6.39-6.74) 2.97 (2.79-3.15) 1.51 (1.40-1.63) 
Youth screening  7.52 (7.35-7.69) 5.66 (5.48-5.84) 2.82 (2.65-3.00) 1.45 (1.34-1.56) 
Youth screening + PN 7.33 (7.14-7.52) 5.44 (5.26-5.62) 2.85 (2.67-3.02) 1.46 (1.35-1.57) 
FSW screening 8.77 (8.59-8.96) 6.47 (6.29-6.65) 2.88 (2.71-3.06) 1.48 (1.36-1.60) 
ANC screening 8.25 (8.06-8.44) 6.26 (6.07-6.46) 2.89 (2.72-3.07) 1.51 (1.40-1.63) 
ANC screening + PN 8.10 (7.90-8.30) 6.13 (5.94-6.33) 2.90 (2.74-3.06) 1.47 (1.36-1.57) 
HIV Care screening 7.57 (7.40-7.74) 5.72 (5.55-5.88) 2.77 (2.61-2.94) 1.41 (1.31-1.52) 
HIV Care screening + PN 7.35 (7.16-7.53) 5.55 (5.37-5.73) 2.68 (2.52-2.84) 1.38 (1.28-1.49) 
Prevalence in youth (aged 15 to 24 years) 
Base scenario* 12.27 (11.96 - 12.57) 6.35 (6.59 - 6.1) 3.91 (3.66 - 4.17) 1.52 (1.40 - 1.64) 
Youth screening 9.10 (8.82 - 9.38) 4.88 (4.65 - 5.10) 3.53 (3.31 - 3.76) 1.41 (1.30 - 1.51) 
Youth screening + PN 8.49 (8.20 - 8.78) 4.34 (4.15- 4.53) 3.49 (3.27 - 3.70) 1.41 (1.30 - 1.52) 
Prevalence in FSWs    
Base scenario* 15.19 (14.51 - 15.88)  24.15 (23.2 - 25.09)  
FSW screening 13.84 (13.22 - 14.46)  22.59 (21.69 -23.49)  
Prevalence in pregnant women   
Base scenario* 12.15 (11.92 - 12.38)  4.27 (4.01 - 4.53)  
ANC screening 11.28 (11.02 - 11.53)  4.16 (3.91 - 4.41)  
ANC screening + PN 11.06 (10.79 - 11.33)  4.14 (3.92 - 4.37)  
Prevalence in patients linked to HIV care   
Base scenario* 8.37 (8.10 - 8.65) 8.24 (7.94 - 8.55) 291 (2.71 – 3.11) .1.95 (1.79 - 2,12) 
HIV Care screening  3,94 (3.76 - 4.12) 3.93 (3.71 - 4.14) 2.21 (2.04 - 2.38) 1.50 (1.36 - 1.64) 
HIV Care screening + PN 3.63 (3.46 - 3.79) 3.70 (3.52 - 3.88) 2.09 (1.93 - 2.26) 1.44 (1.30 - 1.57) 
*Base scenario prevalence estimates are the prevalence levels that would be expected in 2028 in the absence of any screening 
intervention. 
The means and 95% CIs are calculated from the range of model outputs generated when the 100 best-fitting parameter combinations are 
entered into each model. The hypothetical implementation of STI screening programs is simulated as having been initiated in 2018. 











Figure 2: Comparison of modelled effects of a standardised chlamydia screening program on 
chlamydia prevalence, as estimated by different mathematical models. Bars represent the 
percentage reduction in chlamydia prevalence in 16-44 year olds after 10 years of chlamydia 
screening in women only (errors bars represent 95% confidence intervals). For the 
MicroCOSM model, the means and 95% CIs are calculated from the range of model outputs 






















































This study extended an existing individual based model of chlamydia and gonorrhoea in high 
risk South African populations who are already accessing routine healthcare services, making 
them possible targets for opportunistic STI screening. In agreement with empirical studies, 
chlamydia and gonorrhoea prevalence in female youth, FSWs and pregnant women was 
significantly higher than the general population (Table 3). Screening those in HIV care was the 
most effective strategy despite low levels of STI prevalence in females in the subpopulation, 
especially compared to youth. This is due to the fact that they comprise a large fraction of the 
population and they have a higher level of healthcare engagement than youth. Male STI 
prevalence in those in HIV care was slightly lower than male youth possibly explaining why 
the overall efficiency of screening in youth is not that much greater than that of screening 
ART patients. Our model demonstrated that while partner notification results in significantly 
larger reductions in STI transmission, it is not necessary for a sustained reduction in 
population wide chlamydia and gonorrhoea prevalence. 
 
A limitation of our model is that it assumes ART initiation occurs only in the advanced stages 
of HIV infection, though South Africa has recently adopted a policy of treating all HIV-positive 
individuals, regardless of CD4 count (54). For this reason, we have included the untreated HIV-
positive population in WHO stages III and IV in the definition of ‘linked to HIV care’, on the 
assumption that most of these individuals would already be diagnosed or treated under the 
new guidelines. The size of the modelled ‘linked to HIV care’ population in 2018, using this 
definition, is 4.5 million, similar to the number of projected South Africans on ART by 2018 in 
more detailed ART models (4.8 million)(55). Since those on ART receive laboratory monitoring 
at least annually (32), routine HIV care may represent a potential STI screening access point.  
 
When modelling the impact of STI screening, there are concerns about the validity of 
assumptions surrounding sexual contact structure and the natural history of STIs (17). 
Comparative modeling studies  have demonstrated how differences in the specifications of 
heterogeneity in sexual risk behaviour can explain the differing results of previously published 
models evaluating the effectiveness of STI screening (16, 53). A limitation of our analysis is 
that we do not consider this uncertainty when assessing the impact of STI screening. A further 
limitation of this study is that our model has been calibrated using South African STI data from 
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sentinel population reports, as there is currently no routine CT and NG surveillance in South 
Africa. Additionally, the model is not geographically stratified and therefore cannot evaluate 
screening strategies targeting high risk areas.  
 
High rates of bacterial STIs in youth have directed STI screening strategies in the US, UK, 
Sweden and Australia. Based on estimates from the South African GHS of low levels of health 
seeking behaviours in South African youth, we assumed that only 23% of female and 15% of 
male youths would be opportunistically screened per annum in a South African setting (26). 
This study demonstrates that even at such low levels of coverage, opportunistic STI screening 
of youth may be an effective intervention to reduce STI transmission among youth and in the 
general population.  
 
We estimated that ANC targeted screening resulted in a modest reduction in STI transmission 
in comparison to other strategies, despite high screening coverage in this sub-population. 
South Africa has the lowest fertility rate in sub-Saharan Africa (56) and as a result the pregnant 
population comprises a relatively small fraction of the total population.  The modest impact 
of the intervention may be due to the relatively small population size of pregnant women 
when compared to the sizes of the populations targeted in the youth and HIV care screenings 
strategies. While STI screening has been shown to be acceptable and feasible in low-income 
setting where women are already attending antenatal clinics for routine check-ups (57–59), 
there is limited empirical data on its effectiveness at reducing both STI transmission and 
adverse birth outcomes (60, 61).  
 
FSW screening was shown to be the least effective but most efficient screening strategy 
overall. This is partly due to the high prevalence of STIs in FSWs and the small size of the FSW 
population relative to the other subpopulations. The prevalence of chlamydia in FSWs is 
slightly higher than the general population and as a result FSWs do not play a large role in 
sustaining chlamydia transmission at a population level. In contrast, gonorrhoea prevalence 
in FSWs is almost 10 times that of the general population so there is a relatively higher impact 
of FSW screening on gonorrhoea incidence. In line with international STI screening guidelines, 
this study modelled the impact of annual STI screening. There is the potential to increase in 
frequency of screening in high risk group such as FSWs and women in ANC resulting in a larger 
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population wide impact of this intervention. This increased effectiveness might be coupled 
with a  decrease in efficiency as as more frequent screening is less likely to pick up new 
diagnoses per test performed. 
 
Previously published stochastic models of chlamydia screening have reported substantially 
different outcomes (15, 62, 45), creating uncertainty in health policy decision making. We 
considered the standardised screening program described by Kretzschmar et al. to compare 
the predicted impact of a 10-year screening chlamydia program to that estimated by the HPA, 
RIVM and ClaSS models (16). Our model yielded similar estimates to those from the RIVM 
model, but not to the ClaSS and HPA models. The previously published models discussed in 
this study were developed to inform STI screening guidelines in high-income setting (15, 17, 
62). The MicroCOSM model has been parametrized to the South African setting and as a 
consequence we would not necessarily expect the simulated intervention impact to be the 
same across models. 
 
There were substantial differences in the model characteristics and chlamydia natural history 
parameters between the MicroCOSM model and the three previously published models 
(tables S16 and S18). Most notably, our model assumed a significantly longer duration of 
asymptomatic infection and included the possibility of temporary immunity after treatment 
which was not present in the other models. In our model, both the duration of immunity and 
duration of asymptomatic infection were negatively correlated with the impact of the 
screening intervention. The rise in chlamydia infections observed after an initial reduction of 
chlamydia prevalence following chlamydia screening programs has led researchers to 
hypothesize that early treatment of chlamydia may interrupt the development of natural 
immunity resulting in a higher proportion of susceptible individuals in the population (63, 64). 
There is evidence of partial strain-specific immunity after both chlamydia (65, 66) and 
gonorrhoea (67, 68) infections, although the underlying mechanisms that mediate mucosal 
immune interactions with bacterial STIs are poorly understood. A previous modelling study 
demonstrated that including partial immunity for both chlamydia and gonorrhoea resulted in 
estimates that better fit empirical STI prevalence compared to models that do not allow for 
immunity(69). Additionally, models that included temporary immunity predicted significantly 
lower impacts of therapeutic STI interventions, most likely because the direct benefit of the 
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intervention in the short term is offset by a longer-term reduction in the prevalence of 
immunity (69). All other things being equal, we might therefore expect MicroCOSM to 
estimate a lower impact of chlamydia screening than the other models. 
 
However, model differences can also be explained in terms of behavioural factors. The impact 
of the 10-year screening program estimated by the ClaSS model was significantly lower than 
the other models (16, 53). As described by Althaus et al., in comparison to empirical estimates 
this model significantly overstated the extent of heterogeneity in the distribution of 
chlamydia risk (Gini coefficient = 0.84) (53), and previous studies have shown that 
overestimating the extent of heterogeneity in susceptibility to infection means 
underestimating the impact of interventions (70). The HPA model predicted a significantly 
higher impact of the same screening program despite assuming similar heterogeneity in risk 
behaviour when compared to empirical estimates (53) and the MicroCOSM model. It has been 
suggested that this is a result of significantly higher assumed rates of sexual contacts in young 
adults creating an unrealistically high rate of chlamydia in those eligible to be screened (53). 
In addition to this, the HPA model assumes very short durations between partnerships 
resulting in a higher proportion of partners treated through partner notification compared to 
other models (53).The impact of the standardised screening program estimated by our model 
was similar that of RIVM model, which was found to best describe the dynamics of chlamydia 
transmission, sexual partnerships and the distribution of chlamydia infection in the UK 
population (53). Although our allowance for immunity and greater assumed duration of 
asymptomatic infection would be expected to lead to a lesser impact of screening in our 
model compared to the RIVM model, this effect is offset by the greater degree of 
heterogeneity in the distribution of chlamydia risk in the RIVM model (Gini coefficient = 0.46) 
compared to our model (Gini coefficient = 0.37).  
 
A strength of this study is that we utilized a model that has been parametrized to South 
African sexual behaviour and STI epidemiology to investigate the impact of dual screening for 
chlamydia and gonorrhoea in a low-resource setting. Globally, STI screening guidelines that 
have been developed focused on chlamydia specifically, and none have called for gonorrhoea 
screening. This reflects the STI disease burden in high-income countries, in which the 
prevalence of gonorrhoea is negligible compared to the prevalence of chlamydia (1). Due to 
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the overall low prevalence of NG and the threat of increasing antimicrobial resistance, 
opportunistic screening for gonorrhoea is not recommended unless clinically indicated (71).  
In South Africa, however, the prevalence of gonorrhoea is almost half the prevalence of 
chlamydia (4), and there is thus a need for both chlamydia and gonorrhoea screening. A 
deterministic model predicted that in MSM, a short term reduction of  NG prevalence as a 
result of increased treatment may be overshadowed by increased antimicrobial resistance 
and a resultant increased prevalence in the long term (72). Another recent modelling study 
identified higher rates of treatment, as opposed to higher numbers of partners, as the main 
reason for the more rapid emergence of antibiotic-resistant NG in MSM when compared to 
heterosexuals (73). These studies highlight the necessity to consider the spread of NG 
resistance when developing public health recommendations for NG screening (74).   
 
This model assumed STI test specifications consistent with the Cepheid Dual Xpert CT/NG 
rapid POC test that is commonly used in high income countries. The Xpert CT/NG has a 
significantly higher per test cost than commercially available NAATs and the feasibility of 
implementing this test in resource poor settings has yet to be determined (75).  There is a 
need for simple and inexpensive POC tests that can be delivered in a single patient that may 
be utilized in a South African setting. 
 
Conclusion 
While all four screening strategies resulted in reductions in general and key population STI 
transmission, opportunistic chlamydia and gonorrhoea screening of those accessing ART 
treatment and youth represent viable interventions for reducing bacterial STI transmission in 
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Appendix I: Technical Appendix 
 
1. Model of Sexual Behaviour 
The model is an extension of the MicroCOSM (Microsimulation for the Control of South 
African Morbidity and Mortality) model, a previously developed mathematical model of 
heterosexual Human Immunodeficiency Virus (HIV) and sexually transmitted infection (STI) 
transmission in South Africa (1). For the purpose of the STI screening model we will simulate 
the transmission of HIV, Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). Briefly, 
this is an agent based model simulating a representative sample of the South African 
population. The simulation begins with a starting population of 20 000 people in mid 1985, 
and allows for population growth over time. Section 1.1 has been published previously (1) but 
is reproduced here for convenience.  
 
1.1 Risk groups and relationship types 
The population is divided into two broad risk groups: a high risk group (representing 
individuals with a propensity for concurrent sexual partners and commercial sex) and a low 
risk group (representing individuals who do not engage in concurrent partnerships or 
commercial sex). Within each of these risk groups a number of sub-groups (or states) are 
defined, based on the individual’s current relationship status; movements between these 
states occur as individuals form new partnerships and end previously-formed partnerships. 
Figure S1 illustrates the state space that is defined for women in the high risk group.  The 
model distinguishes between short-term (non-cohabiting) and long-term (cohabiting or 
marital) relationships; in addition the model allows for once-off sex acts between sex workers 
and clients. All long-term relationships are assumed to start as non-cohabiting relationships. 
For the sake of simplicity, it is assumed that individuals in the high risk group do not have 
more than two partners at any point in time (although high risk men can have contact with 
sex workers if they have two current partners). It is also assumed in the interests of simplicity 
that individuals do not have more than one long-term partner at any point in time, as rates of 





















Figure S1: Multi-state model of sexual behaviour of ‘high risk’ females 
LT = long-term (spousal). ST = short-term (non-spousal). ‘High’ and ‘low’ refer to the risk group of the sexual 
partner. The model for low risk females is the same as that shown here, except that the shaded states are 
omitted. The model for high risk men is also the same as that shown here, except that the ‘sex worker’ state is 
omitted. 
 
By definition, individuals in the low risk group cannot have more than one partner at any point 
in time, and many of the states that are defined for the high risk group (shaded in grey in 
Figure S1) therefore do not apply to the low risk group. The fraction of the population in the 
high risk group has been set at 35% for men and 25% for women, based on South African 
studies evaluating the fraction of individuals reporting concurrent partnerships (3, 4). Only 
heterosexual partnerships are considered. A detailed description of the specifics of the sexual 










2. Mathematical modelling of STI Transmission and Natural History 
2.1 Mathematical model of chlamydia and gonorrhoea  
 
The mathematical model of the natural history of Gonorrhea and Chlamydia has been 
described previously (1) and has been updated to include opportunistic STI screening as 
illustrated in Figure S2 and summarised in Table S1. The models used for CT and NG are 
identical in structure but different parameters are assigned to each. In short, susceptible 
individuals become infected at rate λ, and newly infected individuals may develop symptoms 
or remain asymptomatic. Both states may result in temporary immunity after spontaneous 
resolution of infection or after receiving treatment. Symptomatic individuals seek treatment 
at rate υ, which is successful at curing the infection with the probability ψ. The natural history 
parameters assigned to chlamydia and gonorrhea have been previously described (1) and are 



















Figure S2: Multi-State model of the natural history of chlamydia and gonorrhoea  
Updated from the HIV-STI model (1) to include opportunistic STI screening 
 
Both symptomatic and asymptomatic individuals will be screened at rate α, which is a product 
of three independent probabilities: 
(1) The probability of attending a health service where screening is available 






υψ (1 – φ3)





λ(1 – φ1)αψ(1 – φ2)
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(3) The probability of accepting a screening test 
 These parameters have been calculated separately for each population based on estimates 
from the literature.   
For both CT and NG, probability distributions were specified to represent uncertainty around 
key natural history and transmission parameters as described previously (1). A likelihood 
function was defined for each STI to represent the degree of model consistency with South 
African STI prevalence data, for a given set of parameter combinations. For each STI, a sample 
of 20,000 parameter combinations were drawn from the probability distributions and the 100 
parameter combinations that yielded the highest likelihood values were selected as 
summarized in table S2 and S3. These 100 parameter combinations are used to generate the 
results presented in the current paper. 
 
In the previous application of the model, immunity following successful treatment of 
asymptomatic infection was not considered, since the model considered only treatment of 
symptomatic infection. Due to lack of data on immunity following successful treatment, we 
assume here that the extent of immunity following the successful treatment of asymptomatic 











Table S1: Natural history and transmission parameters 
Symbol Definition 
φ1 Proportion of people who become symptomatic 
φ2 Proportion of people temporarily immune after experiencing resolution of an 
asymptomatic infection after treatment 
φ3 Proportion of people temporarily immune after experiencing resolution of a 
symptomatic infection after treatment  
σ1 Rate at which symptomatic people recover in the absence of treatment 
σ2 Rate at which asymptomatic people recover in the absence of treatment 





 Table S2: Parameters for Chlamydial infection 
* SM = syndromic management 
 
 
Table S3: Parameters for Gonorrheal infection 














% of cases that become symptomatic     
     Male φ1 36.7% (26.5% -45.0%) 
     Female  11.6% (7.0% -15.9%) 
Average duration if untreated (weeks)     
     Symptomatic 1/σ2 15.0 (10.2- 19.5) 
     Asymptomatic  106.6 (96.7 - 116.6) 
Average duration of immunity (weeks) 1/σ3 295 (241 - 343) 
Proportion immune after treatment cure φ2 73.2% (59.5% - 88.4%) 
Transmission probability per act of sex     
     Male-to-female - 16.2% (11.8% - 20.5%) 
     Female-to-male - 9.75% (7.13% - 15.4%) 
Fraction of symptoms correctly treated  
     prior to introduction of SM* 






% of cases that become symptomatic     
     Male φ1 86.6% (83.5% -89.6%) 
     Female  29.9% (22.6% - 39.2%) 
Average duration if untreated (weeks)     
     Male 1/σ2 34.0 (25.8 – 38.3) 
     Female  33.6 (29.5 – 38.9) 
Average duration of immunity (weeks) 1/σ3 48.8 (41.8 - 61.8) 
Proportion immune after treatment cure φ2 40.1% (20.4% - 59.0%) 
Transmission probability per act of sex     
     Male-to-female - 45.9% (40.1% - 53.1%) 
     Female-to-male - 23.7% (19.8% - 27.2%) 
Fraction of symptoms correctly treated  
     prior to introduction of SM* 






2.2 Mathematical model of STI screening  
 
We have introduced the components of a hypothetical 10-year screening intervention while 
keeping parameters describing transmission and duration of infection the same as in the 
original model (1). 
 
Four targeted screening programs are simulated: 
1. Youth screening: Males and females aged 15-24 are eligible for annual screening. This 
screening strategy is in line with global Chlamydia screening policies (5, 6) 
2. Antenatal care (ANC) screening: The Centres for Disease Control recommend antenatal 
STI screening for CT and NG for all women at the onset of prenatal care, and again in the 
third trimester for women who are younger than 25 years or at increased risk (7). Our 
model does not simulate the duration of pregnancy but rather occurrence of a new birth. 
Because of this, antenatal screening is simulated as occurring at the time of birth. 
3. Female Sex Worker (FSW) screening:  All FSWs are eligible for annual screening. 
4. HIV Care Screening: HIV positive individuals, above the age of 14 and either on ART or in 
the symptomatic stages of disease (WHO stages III and IV) are eligible for annual STI 
screening. Recent changes in South African guidelines recommend that all HIV positive 
individual should be initiated onto ART treatment regardless of CD4 counts (8), therefore 
theoretically all individuals with a known HIV positive status should be accessing ART.  
 
For the populations in which the coverage of STI screening is known (ANC), a single probability 
of screening is applied. For populations in which the coverage of screening in not known 
(youth, FSW and ART patients), an annual rate of screening has been calculated as the product 
of the the probability of annual health care utilisation, STI screening acceptability and 
screening coverage. A random number between 0 and 1 is assigned to each eligible individual 
at the start of each weekly time step. All individuals assigned random probabilities below the 
probability of screening are screened for STIs and treated with a rate of success described by 
the model above (Figure 1).  
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In all scenarios individuals are screened for both chlamydia and gonorrhoea simultaneously 
under the assumption that point of care (POC) testing would be performed with a POC test 
with dual testing capabilities, such the Cepheid GeneXpert CT/NG (Xpert) assay (9). The 
GeneXpert CT/NG is considerably more accurate than other commercially available POC tests 
(10) and demonstrates higher sensitivities using endocervical/urethral samples in comparison 
to urine samples (9). Despite the slightly reduced sensitivity, urine based STI testing yields 
higher rates of acceptability compared to more invasive sample collection (11–13). Based on 
this, the sensitivity of STI testing in youth, FSW and HIV care targeted screening scenarios is 
assumed to be the same as the GeneXpert sensitivity for urine samples (97.4% in females and 
97.5% in males for CT, 95.6% in females and 98.0% in males for NG) (9). STI testing using 
vaginal swab collection has been found to be acceptable when implemented as part of routine 
antenatal check-ups (14–16) and the sensitivity of the screening test in the antenatal strategy 
is therefore assumed to be the same as the GeneXpert sensitivity for vaginal samples (97.4% 
for CT and 100% for NG)(9).  
 
2.2.1 Partner notification 
Partner notification (PN) has been identified as an integral component of prevention of 
curable STIs, specifically STIs such as CT which is predominately asymptomatic (17). PN is 
currently recommended as part of global STI screening programs and involves identifying 
partners of patients that test positive for curable STIs (index cases) so that they may be 
screened or presumptively treated (17). Index cases in this model can have a maximum of two 
current partners. If screening produces a positive result, both primary and secondary (when 
applicable) partners are screened with a probability of 50% based on estimates from literature 
(Table S5). These estimates are based on studies implementing standard patient referral 
whereby index cases are given the responsibility of notifying partners (Table S5).  Partners are 
treated with the same rate of success as index cases. In this model only current sexual 
partners are considered eligible for partner notification. It is currently unknown whether 
index cases are more likely to notify current as opposed to former partners of their STI status, 
but mathematical modelling has shown that notification of only current partners is sufficient 
to achieve population level reduction in STI prevalence (17). Women engaging in sex work are 
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assumed not to form short-term or long-term relationships during the periods in which they 
are active as sex workers. Due to this, partner notification cannot be simulated in the FSW 
population.  
 
2.2.2    Partner notification sensitivity analysis 
Previously published studies of CT screening have assumed that primary and secondary 
partners would be notified and screened with equal probability (18). In order to investigate 
this further we ran a sensitivity analysis comparing youth targeted screening utilizing three 
different partner notification scenarios. 
Run 1: Primary and secondary partners are screened with equal probability (50%). (This is the 
default scenario.) 
Run 2: Only primary partners are screened, all with the same probability (50%). 
Run 3: Only primary partners are screened. Primary partners that are marital partners are 
screened with a higher probability (100%) compared to non-marital partners (50%).  
A comparison of these scenarios revealed that the highest number of partners screened 


















Figure S3: Comparison of number of partners screened under 3 partner notification scenarios 
over 10 years of youth targeted screening. Shapes represent mean number of partners 
screened from the range of model outputs generated when the 100 best-fitting parameter 
combinations are entered into each model (error bars represent 95% CIs). The population 
grew dynamically over the 10-year screening period with an average population size close to 















































Table S4: % increase in STI estimates for general population (aged 15 to 49) with differing 
partner notification scenarios, in the context of youth-targeted screening 
  Run 1 vs. Run 2 Run 1 vs. Run 3  Run 3 vs. Run 2 
% increase in cumulative incidence (2018 -2028)  
             Chlamydia  -1.05 (0.26-1.83) -0.20 (-0.50-0.90) 0.88 (0.23-1.53) 
             Gonorrhea  0.15 (-1.58-1.28) -1.38 (-0.58-3.35) -1.00 (-2.64-0.64) 
 
             Chlamydia Females -1.58 (-0.26-3.42) 0.02 (-1.53-1.49) 1.91 (0.05-3.76) 
 Males -1.46 (-0.33-3.26) -0.64 (-1.01-2.30) 1.21 (-0.66-3.09) 
             Gonorrhea Females -3.96 (-0.47-8.39) -2.51 (-1.75-6.78) 3.23 (-0.88-7.35) 
 Males -7.34 (-1.56-13.13) -7.03 (1.75-12.32) 2.41 (-2.4-7.21) 
 
 
3. Estimation of screening parameters 
Where possible, the health seeking behaviour of different South African populations has been 
calculated from South African national survey data and epidemiological studies on the impact 
and behaviours associated with STI screening. In the cases where there is no current data on 
these behaviours in the South African population, data sources from other countries, where 
screening for CT and NG has been implemented, have been considered. Studies selected for 
parameterization comprise of observational studies, where investigators have reported 
samples of youths, pregnant women, female sex workers and those in HIV care, in South Africa 
and other countries.  
 
The probability of antenatal screening for bacterial STIs is assumed to be 0.71, equal to the 
current coverage of antenatal syphilis screening in South African women (19). This probability 
is applied to all pregnant women at the occurrence of childbirth.  
 
For all other sub-populations, a screening coverage of 80% is assumed from 2018 until 2028 
for all screening strategies, i.e. eligible individuals who attend health facilities are assumed to 
be offered screening with 80% probability. Youth are assumed to access healthcare at an 
annual rate of 0.48 for females and 0.32 for males (20).  Based on estimates from literature 
on the acceptability of STI screening using urine based testing, youth acceptability of STI 
 81 
screening is assumed to be 60% (Table S6). There is no empirical data on the STI screening 
acceptability in South Africans linked to HIV care. South African HIV treatment guidelines 
recommend viral load testing 6 and 12 months after initiating ART treatment and annually 
thereafter (21). As this population is undergoing regular viral load testing, we can assume that 
the majority of those on ART attend a clinic at which STI screening may be offered at least 
annually. Even if patients are in WHO stages III/IV but not on ART, it is likely that they would 
attend HIV services regularly to receive treatment for opportunistic infections, and STI 
screening could also be offered at these services. We assume that 90% of those on ART or in 
WHO stages III and IV access healthcare annually and would be amenable to opportunistic STI 
testing. Based on literature regarding FSWs within South Africa and internationally, FSWs are 
assumed to access healthcare with an annual rate of 0.50 (Table S7) and FSWs acceptability 





Table S5: Literature review of Partner Notification rates 
Study Year Sample Location STI Partner notification type Proportion of partners 
screened 
Estcourt et al. (22) 2015 Females aged 16 +, in 
GP, GUM and 
pharmacies 
East London, United 
Kingdom 
CT & NG Standard referral 45% (N=102) 
Herzog et al. (23) 2011 Men and women 
attending GUM clinics 
UK CT Not recorded 47% (N =4616) 
Cameron et al. (24) 2009 Women attending FPCs 
or GUM clinics 
Edinburgh CT Standard referral 41% (N=134) 
Golden et al.  (25) 2005 Heterosexual men and 
women  
Washington, USA CT & NG  Standard referral 78% (N= 1375) 
Kissinger et al. (26) 2005 Men attending an STD 
clinic 
New Orleans NG & CT Standard referral 71% (N=285) 
Low et al. (27) 2005 Men and women visiting 
primary care facilities 
and GUM clinics 
Bristol and 
Birmingham, UK 
CT Standard referral 52.9% (N= 68) 
van de Laar et al. 
(28) 
1997 Men and women 
attending an STI clinic 
Amsterdam, 
Netherlands 
CT & NG Self-referral using referral cards 40% (N = 580) 
CT = Chlamydia trachomatis , FPC = family planning clinic, GUM = genitourinary medicine,  NG = Neisseria gonorrhoeae, UK = United Kingdom, USA = United States of America
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CT = Chlamydia trachomatis, ED = emergency department, FP = family planning, LCR = ligase chain reaction, NG = Neisseria gonorrhoeae, PCR = polymerase chain reaction, SDA = strand 
displacement amplification 
Table S6: Literature review of Youth STI screening acceptability 
Study Year Sample Location STI Test Screening acceptability 
Goyal et al. (29) 2016 14-21-year-old asymptomatic males and 
females presenting to ED  
Washington, DC CT & NG Urine based PCR 59% (N= 553) 
Goldenkranz et al. 
(30) 
2012 10-14-year-old females visiting Title FP X 
clinics 
Region X (Alaska, 
Idaho, Oregon and 
Washington) 
 
CT Not reported 34.5% (N= 2697) 
  15-19-year-old females visiting Title FP X 
clinics 
 40.7% (N = 56 400) 
  20-24-year-old females visiting Title FP X 
clinics 
 40.7 % (N= 81 180) 
Marrazzo et al. (31) 2007 Asymptomatic males in adolescent 
primary care 
Baltimore, Denver, 
San Francisco and 
Seattle 
CT Urine based PCR or SDA 61% (N= 93) 
  Asymptomatic males in adolescent 
school based clinics 
   49% (N= 412) 
  Asymptomatic males in Juvenile 
detention centers 
   68% (N=879) 
Kent et al. (32) 2004 Male and female students at 4 high 
schools 
San Francisco CT & NG Urine based LCR 14% (N= 4497) 
Monroe et al. (33) 2003 14 -20-year-old asymptomatic males 
and females presenting to ED 
 
Texas 
CT & NG Urine based LCR 71% (N= 1231) 
 
       
Shafer et al. (34) 2002 14-18-year-old females in schools Northern Caroline CT SDA 47% (N= 1071) 
Cohen et al. (13) 1999 9-12th grade high school male and 
females 
Louisiana CT Urine based LCR 52 – 65% (N= 6000+) 
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Health Seeking in the last year (at least once) 
General STI Screening 
Kohler et al. (35) 2016 FSWs ≥14 Peru Not reported 52.3 -57.2 %  
SAHMS Final Report 
(36) 
2015 FSWs ≥ 16 Johannesburg 53.8% Not reported 
Cape Town 36.2% 
Durban 58.8% 
Wong et al. (37) 2015 FSWs Hong Kong Not reported 45% (N = 340) 
Richter et al. (38) 2014 FSWs South Africa 60% interacted with health service in the last 
month 
Not reported 





Table S8: Literature review of FSW STI Screening acceptability 
Study Year Sample Location STI Test Screening acceptability 
Wong et al. (37) 2015 FSWs Hong Kong HIV, Syphilis, CT 
& NG  
Self -collected Urine/ physician 
collect ectocervical swab based 
NAAT 
41.6% (N=818) 
Morton et al. (40) 1999 Male, female and 
transsexual sex-workers  
Melbourne CT, NG & TV Self-collected tampon (females) 
or urine (males/ transsexuals) 
based PCR 
78% (N=81) 




Clinician obtained cervical 
samples based direct 
immunofluorescence 
100% (N=145) 
BV = Bacterial Vaginosis , CT = Chlamydia trachomatis, HIV = Human Immunodeficiency Virus,  NAAT = Nucleic acid amplification test ,NG = Neisseria gonorrhoeae, PCR = polymerase chain 
reaction, TV = Trichomonas vaginalis
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4. Correlates of Model Outputs 
Tables S9 and S10 show the relationship between natural history and transmission 
parameters of chlamydia and gonorrhea and the reduction in STI transmission using 
different screening strategies. This relationship is described by the Pearson correlation 
coefficient, and was calculated using the 100 parameter combinations that yielded the 
best fit to the STI prevalence data. When considering which parameters had the 
largest effect on the impact of the screening intervention, a number of points emerge: 
 
• The CT transmission probabilities were positively correlated with the reduction in 
chlamydia incidence and prevalence.  
• The average duration of CT immunity was negatively associated with a reduction 
in chlamydia incidence and prevalence. This is because the direct benefit of the 
intervention in the short term is offset by a longer-term reduction in the 
prevalence of immunity (42), and longer durations of immunity are associated 
with greater offsets.  
• The duration of asymptomatic CT infection was also negatively associated with 
impact of the screening intervention.  Since the average duration of asymptomatic 
infection is strongly positively associated with average duration of immunity 
(correlation = 0.61), it is likely that the association is confounded by the immunity 
parameter and it is the latter that is driving the observed association.  
• For the most part, the same relationship between the average duration of 
immunity was not observed for NG. The strongest relationships between 
immunity parameters for CT and the impact of the screening intervention were 
observed in the screening strategies that showed the largest impacts (targeted at 
youth and HIV Care in comparison to ANC and FSWs). Only in the case of FSW 
screening, targeting a subpopulation with the highest NG prevalence, was the 
impact of screening negatively correlated with the average duration of NG 
immunity. We suspect that NG immunity is generally associated with the impact 
of the screening intervention but the low population prevalence of NG in this 
model results in less statistical power to observe this relationship.  
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• The proportion of female NG cases that become symptomatic was positively 
correlated with the impact of the screening intervention. In scenarios in which 
there is a higher proportion of symptomatic STI cases, there would be a higher rate 
of health seeking behaviour resulting in lower baseline prevalence on average. 
Since NG is closer to the threshold of persistence relative to CT (i.e. closer to R0 = 
1), this may result in NG becoming extinct in scenarios where a larger proportion 
of cases become symptomatic, resulting in the same intervention having a 
relatively higher impact on NG prevalence compared to CT.  
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% of cases that become 
symptomatic 
Average duration (in years)  
Scenario 
% Change relative 
to baseline 











Youth Screening  
     Cumulative incidence (2018 -2028) 0.16 0.29** 0.02 -0.02 -0.15 -0.33** -0.28** -0.02 -0.01 
     Prevalence (2028) 
 
Females (15 – 49) 0.17 0.16 -0.06 -0.02 -0.09 -0.46** -0.13 -0.24* 0.01 
 
Males (15 – 49) 0.13 0.22* -0.02 -0.10 -0.15 -0.26** -0.08 -0.01 -0.03 
 
Females (15 – 24) 0.07 -0.01 -0.15 -0.11 0.01 -0.36** -0.22* -0.12 0.05 
  Males (15 – 24) 0.12 0.15 -0.14 -0.10 0.04 -0.22* -0.14 0.10 0.07 
Youth Screening with Partner Notification 
     Cumulative incidence (2018 -2028) 0.24* 0.24* 0.08 0.14 0.05 -0.38** -0.53** -0.12 0.01 
     Prevalence (2028) 
       Females (15 – 49) 0.26** 0.11 -0.14 -0.03 0.07 -0.57** -0.33** -0.30** -0.03 
 
 Males (15 – 49) 0.13 0.22* -0.02 -0.10 -0.15 -0.26** -0.08 -0.01 -0.03 
  Females (15 – 24) 0.14 0.02 -0.14 -0.09 0.08 -0.46** -0.33** -0.21* -0.04 
   Males (15 – 24) 0.03 0.19 0.02 -0.08 0.15 -0.34** -0.19 -0.25* -0.01 
Female Sex Worker 
    Cumulative incidence (2018 -2028) 0.22* 0.03 0.01 0.09 -0.22* -0.11 -0.02 0.04 0.02 
    Prevalence (2028) 
        Females (15 – 49) 0.20* 0.00 -0.07 0.18 -0.11 -0.12 0.00 -0.05 -0.07 
             Males (15 – 49) 0.14 0.05 -0.04 0.09 -0.18 -0.03 -0.09 0.09 -0.02 
    FSW 0.05 0.04 0.00 0.07 -0.09 0.03 0.01 0.08 -0.02 
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Table S9 continued 
Antenatal Screening  
    Cumulative incidence (2018 -2028) 0.12 0.14 0.02 -0.05 -0.21* -0.17 -0.19* 0.00 0.00 
    Prevalence (2028) 
     Females (15 – 49) 0.11 0.05 -0.07 0.04 -0.15 -0.14 0.00 -0.08 -0.04 
         Males (15 – 49) 0.00 0.14 0.09 -0.04 -0.18 0.05 -0.02 0.08 0.00 
 
ANC 
0.13 0.03 -0.04 0.05 -0.16 -0.11 -0.07 -0.04 0.00 
Antenatal Screening with Partner Notification 
    Cumulative incidence (2018 -2028) 0.15 0.24* 0.12 -0.03 -0.17 -0.20* -0.10 -0.04 -0.09 
    Prevalence (2028)           
      Females (15 – 49) 0.12 0.26** 0.07 0.06 -0.12 -0.21* -0.12 -0.06 -0.08 
 Males (15 – 49) 0.09 0.27** 0.07 -0.01 -0.15 -0.07 -0.18 0.06 -0.10 
 ANC 0.10 0.25** 0.05 0.05 -0.10 -0.19* -0.15 -0.06 -0.06 
HIV Care Screening  
    Cumulative incidence (2018 -2028) 
0.27*
* 0.33** 0.05 0.08 -0.17 -0.13 -0.33** 0.18 -0.10 
Prevalence (2028)           
 Females (15 – 49) 0.17 0.06 -0.12 0.09 -0.16 -0.11 -0.18 0.03 -0.12 
 Males (15 – 49) 0.09 0.08 0.03 0.02 -0.24* 0.03 -0.17 0.09 -0.15 
 Females HIV care 0.21* 0.17 -0.09 0.03 -0.06 -0.53** -0.26** -0.24* -0.25* 
 Males HIV care 0.19 0.10 -0.08 -0.05 -0.10 -0.41** -0.31** -0.14 -0.11 
HIV Care Screening with Partner Notification 
    Cumulative incidence (2018 -2028) 0.21* 0.41** 0.19 -0.04 -0.12 -0.18 -0.26** 0.14 -0.02 
Prevalence (2028)           
 Females (15 – 49) 
0.28*
* 0.23* 0.03 0.04 -0.06 -0.13 -0.05 0.04 -0.06 
 Males (15 – 49) 0.16 0.31** 0.09 -0.03 -0.18 0.00 -0.08 0.17 -0.07 
 Females HIV care 0.22* 0.21* 0.01 0.13 0.06 -0.38** -0.27** -0.13 -0.23* 
 Males HIV care 0.14 0.11 -0.10 0.00 -0.01 -0.32** -0.29** -0.04 -0.05 










% of cases that become 
symptomatic 
Average duration (in years) Immunity 
Scenario 
% Change relative 
to baseline 
















Youth Screening  
     Cumulative incidence (2018 -2028) -0.01 -0.02 0.09 0.07 -0.03 -0.22* -0.17 -0.03 -0.08 
     Prevalence (2028) 
 
Females (15 – 49) 0.03 -0.12 -0.11 0.16 -0.01 0.03 -0.06 0.04 0.08 
 
Males (15 – 49) 0.03 -0.10 -0.09 0.15 -0.03 -0.05 -0.11 0.02 0.01 
 
Females (15 – 14) 0.02 -0.07 -0.16 0.05 -0.12 -0.09 -0.13 0.06 0.02 
  Males (15 – 24) 0.01 0.13 0.06 0.09 -0.05 -0.11 -0.14 0.06 0.03 
Youth Screening with Partner Notification 
     Cumulative incidence (2018 -2028) -0.08 0.11 -0.06 0.09 -0.03 0.00 -0.08 0.05 -0.14 
     Prevalence (2028) 
       Females (15 – 49) -0.13 0.06 -0.09 0.20* 0.02 0.12 -0.07 0.08 0.01 
 
 Males (15 – 49) -0.08 0.03 -0.15 -0.09 -0.04 -0.06 0.11 -0.02 -0.18 
  Females (15 – 14) -0.12 0.12 0.00 0.07 -0.05 -0.04 -0.16 0.17 0.01 
   Males (15 – 24) -0.07 0.07 0.00 0.07 -0.11 -0.03 -0.24* 0.14 0.01 
Female Sex Worker 
    Cumulative incidence (2018 -2028) 0.01 -0.07 0.07 0.16 -0.11 -0.05 -0.30** 0.14 -0.07 
    Prevalence (2028) 
        Females (15 – 49) -0.01 -0.07 -0.05 0.25** 0.15 0.04 -0.14 0.13 0.08 
             Males (15 – 49) -0.06 -0.05 -0.05 0.20* 0.08 0.07 -0.15 0.13 -0.06 
    FSW 0.09 -0.09 0.12 0.15 0.10 0.07 -0.05 -0.03 -0.02 






Table S10 continued 
Antenatal Screening  
    Cumulative incidence (2018 -2028) -0.05 -0.01 -0.04 0.24* 0.12 -0.10 -0.06 -0.02 -0.06 
    Prevalence (2028) 
     Females (15 – 49) -0.01 -0.04 -0.11 0.27** 0.04 0.05 -0.17 0.10 0.03 
         Males (15 – 49) -0.01 -0.13 -0.11 0.25** 0.06 0.08 -0.18 0.12 0.00 
 
ANC 
0.01 -0.04 -0.11 0.24* 0.03 0.05 -0.16 0.11 0.03 
Antenatal Screening with Partner Notification 
    Cumulative incidence (2018 -2028) -0.03 -0.01 -0.08 0.18 0.01 0.00 -0.05 -0.06 0.04 
    Prevalence (2028)           
      Females (15 – 49) -0.09 -0.02 0.02 0.14 0.08 0.14 -0.05 0.02 0.06 
 Males (15 – 49) -0.07 -0.03 0.08 0.21* 0.13 0.17 -0.08 0.07 0.00 
 ANC -0.08 -0.04 0.00 0.12 0.08 0.16 0.00 0.00 0.08 
HIV Care Screening  
    Cumulative incidence (2018 -2028) 0.04 0.04 -0.03 0.05 -0.12 -0.11 -0.21* 0.09 0.00 
Prevalence (2028)           
 Females (15 – 49) -0.06 0.09 0.08 0.20* -0.06 0.03 -0.11 0.05 0.03 
 Males (15 – 49) -0.09 0.07 0.04 0.20* -0.07 0.04 -0.12 0.08 -0.05 
 Females HIV care 0.08 0.05 0.09 0.18 0.04 -0.10 -0.23* 0.06 -0.02 
 Males HIV care -0.10 0.09 0.13 0.10 -0.16 0.16 -0.16 0.14 -0.05 
HIV Care Screening with Partner Notification 
    Cumulative incidence (2018 -2028) 0.05 0.11 0.00 0.34** -0.02 -0.04 -0.14 -0.04 0.05 
Prevalence (2028)           
 Females (15 – 49) -0.14 0.03 -0.06 0.25** 0.01 0.26* -0.10 0.15 0.03 
 Males (15 – 49) -0.19* 0.01 -0.06 0.25** -0.07 0.24 -0.20* 0.18 -0.02 
 Females HIV care 0.09 -0.06 -0.03 0.03 0.12 -0.01 -0.16 0.17 -0.01 
 Males HIV care -0.10 0.04 0.00 0.03 -0.25* 0.21 -0.14 0.12 -0.05 
* p <0.05     **p <0,01
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5.   Additional model outputs 
 
Table S11: Cumulative incidence over the 10-year targeted screening program  
The population grew dynamically over the 10-year screening period with an average population size close to 36000 mid-way through the 
screening period.   
*Baseline incidence estimates were calculated over the same 10-year period as the hypothetical screening intervention 
The means and 95% CIs are calculated from the range of model outputs generated when the 100 best-fitting parameter combinations are 




Table S12: Estimated impact of targeted screening programs on population level prevalence 
(aged 15 to 49) after the implementation of a 10-year targeted screening program 
 % Reduction in prevalence 10th Year (95% CI) 
 Chlamydia Gonorrhea 
Scenario Females Males Females Males 
Youth vs. Baseline 15.09 (13.82-16.35) 13.75 (12.25-15.25) 3.34 (-0.50-7.18) 1.29 (-3.56-6.15) 
Youth PN vs. Baseline 17.38 (16.00-18.75) 17.29 (15.91-18.67) 2.30 (-1.52-6.13) 1.12 (-3.67-5.91) 
Youth vs. Youth PN 2.52 (1.17-3.87) 3.75 (2.20-5.30) -2.77 (-6.54-1.00) -2.34 (-6.71-2.03) 
FSW vs. Baseline 0.94 (-0.23-2.10) 1.34 (-0.02-2.69) 1.41 (-2.35-5.18) 0.34 (-4.24-4.91) 
ANC vs. Baseline 6.94 (5.72-8.15) 4.64 (3.23-6.04) 0.27 (-3.98-4.52) -2.61 (-7.29-2.07) 
ANC PN vs. Baseline 8.70 (7.32-10.07) 6.66 (5.18-8.14) 0.39 (-2.93-3.71) -0.75 (-5.25-3.74) 
ANC vs. ANC PN 1.66 (0.14-3.18) 1.89 (0.45-3.33) -2.96 (-7.28-1.36) -0.84 (-5.27-3.60) 
HIV Care vs. Baseline 14.54 (13.44-15.63) 12.85 (11.52-14.17) 4.74 (0.94-8.54) 3.67 (-1.37-8.72) 
HIV Care PN vs. Baseline 17.12 (15.81-18.44) 15.45 (13.93-16.96) 8.29 (4.76-11.83) 5.86 (1.40-10.32) 
HIV Care vs. HIV Care PN 2.87 (1.43-4.30) 2.79 (1.21-4.36) 0.97 (-3.76-5.70) -1.69 (-7.33-3.94) 
The means and 95% CIs are calculated from the range of model outputs generated when the 100 best-fitting parameter combinations are 
entered into each model. The hypothetical implementation of STI screening programs is simulated as having been initiated in 2018. 








Cumulative incidence over 
10 years (95% CI) 
% Reduction in Cumulative incidence 
relative to baseline 
Scenario Chlamydia Gonorrhea Chlamydia Gonorrhea 
Baseline* 11292 (10866-11718) 19168 (18004-20333)   
Youth Screening  
Without PN 10670 (10239-11101) 18614 (17454-19774) 5.72 (5.05-6.39) 3.00 (1.67-4.32) 
With PN 10496 (10061-10931) 18489 (17346-19632) 7.37 (6.62-8.11) 3.4 (2.07-4.72) 
FSW Screening  
Without PN 11216 (10790-11642) 18737 (17567-19908) 0.68 (0.18-1.19) 2.40 (1.33-3.47) 
Antenatal Care screening  
Without PN 11092 (10661-11523) 18869 (17731-20007) 1.87 (1.34-2.40) 1.20 (-0.14-2.55) 
With PN 10991 (10565-11418) 18905 (17765-20045) 2.77 (2.2-3.34) 1.05 (-0.25-2.35) 
HIV Care screening 
Without PN 10412 (9996-10827) 18214 (17061-19368) 7.94 (7.33-8.56) 5.20 (4.02-6.38) 
With PN 10184 (9768-10601) 18130 (16996-19264) 10.05 (9.33-10.78) 5.45 (4.06-6.83) 
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Table S13: Estimated impact of targeted screening programs in key populations after the 
implementation of a 10-year targeted screening program 
 Chlamydia Gonorrhoea 
Scenario Females Males Females Males 
Youth targeted screening: % Reduction in Youth (aged 15 to 24) prevalence 
Youth vs. Baseline 25.70 (24.1 - 27.3) 23.06 (20.75 - 25.37) 7.14 (2.59 - 11.68) 3.06 (-2.85 - 8.97) 
Youth PN vs. Baseline 30.66 (28.85 - 32.46) 31.4 (29.34 - 33.45) 7.99 (3.3 - 12.68) 2.23 (-4.56 - 9.02) 
FSW targeted screening: % Reduction in FSW prevalence 
FSW vs. Baseline 5.93 (1.24 - 10.61)  4.88 (1.54 - 8.23) 
 
ANC targeted screening: % Reduction in pregnant women prevalence 
ANC vs. Baseline 7.16 (5.95 - 8.37)  0.14 (-4.20 - 4.49)  
ANC PN vs. Baseline 9.00 (7.61 - 10.4)  0.65 (-2.77 - 4.07)  
HIV Care targeted screening: % Reduction in STI prevalence in patients in HIV care 
HIV Care vs. Baseline 52.58 (50.72 - 54.44) 51.97 (49.66 - 54.28) 22.5 (18.2 - 26.80) 18.3 (11.54 - 25.05) 
HIV Care PN vs. Baseline 56.27 (54.44 - 58.09) 54.72 (52.68 - 56.75) 27.26 (23.37 - 31.14) 20.04 (12.46 - 27.62) 
The means and 95% CIs are calculated from the range of model outputs generated when the 100 best-fitting parameter 
combinations are entered into each model. The hypothetical implementation of STI screening programs is simulated as 
having been initiated in 2018, and the reduction in incidence and prevalence is calculated relative to the level that would 
have been expected in the absence of any screening program.  



































6.   Standardised screening programme 
 
Table S14: Sexual partner estimates and chlamydia prevalence 
 Age (years) 
CT prevalence 
prior to screening %(%) 
Average annual 
Partners 
Effective Contact  
Rate * 
Females 16 - 19 11.83 (11.46-12.2) 1.73 (1.73-1.74) 4.02 (4.01-4.02) 
 20 - 24  15.34 (14.98-15.70) 2.68 (2.68-2.69) 4.02 (4.02-4.03) 
 25 - 29 11.52 (11.25-11.78) 2.56 (2.55-2.56) 3.70 (3.70-3.71) 
Males 16 - 19 4.30 (4.08-4.53) 0.89 (0.88-0.89) 3.51 (3.50-3.52) 
 20 - 24  9.25 (8.91-9.59) 2.16 (2.15-2.17) 3.86 (3.85-3.87) 
 25 - 29 9.93 (9.64-10.22) 2.59 (2.58-2.60) 3.80 (3.79-3.81) 
The means and 95% CIs are calculated from the range of model outputs generated when the 100 best-fitting parameter combinations are 
entered into each model. The hypothetical implementation of STI screening programs is simulated as having been initiated in 2018. 
* Effective contact rate (c), is calculated as c = m + v/ m, where m is the mean number of sex partners per year and v its variance. This is a 
measure of the heterogeneity of sexual partnerships that can be compared across network models with different structures (18) 
 
 
Table S15: Chlamydia natural history parameters specified for individual-based stochastic 
simulation models of Chlamydia transmission  
Parameter RIVM ClaSS HPA MicroCOSM* 
Transmission probability per act of sex     
Male-to-female 0.11 0.154 0.0375 0.162 
Female –to-male 0.11 0.122 0.0375 0.098 
Frequency of sex acts     
 1/day casual 
0.25/day 
steady 




5/month long term (declining by 
50% for every 20 -year increase in 
age) 
% of cases that become symptomatic 
Male 0.50 0.75 0.00 0.37 
Female 0.30 0.30 0.045 0.11 
Average duration asymptomatic infection (days) 
Males  200 200 180  683 
Females 300 200 180 711 
Average duration symptomatic infection (days) 
Males 33 33 30  15 
Females 40 40 30 30 
Proportion immune after treatment 
cure 
0 0 0 73.2 
Average duration of immunity (days) 0 0 0 2065 















Table S16: Characteristics of individual-based stochastic simulation models of Chlamydia 
transmission used to simulate standardised screening program (Updated from Kretzschmar 
et al. (18))  
 
 RIVM model ClaSS HPA MicroCOSM 
Simulation method 
 Discrete time step simulation. Movement between STI states are calculated at daily intervals. 
 
Events occur each day with probabilities assigned or drawn from distributions 
Discrete time step simulation. 
Movements between STI states are 
calculated at weekly intervals. 
Model population size 
 Closed population of 40 000 Closed population of 40 000 Closed population of 40 000 Population grows dynamically reaching 
a size of approximately 36 000 mid-
way through the screening program  
Model population age 






All ages. Projection begins with South 
Africa population profile in mid 1985, 
50.39% births are male 
Sexual activity levels 
 Two risk groups  
 
Core (5% of 15–35-year-old 
women and men)  
 
Non-core (95% 15–35-year-
old men and women, 100% 
35+- year-old men and 
women)  
Three risk groups  
 
High (5% of 15–35-year-old 
women, 9% of 15–35-year-
old men)  
 
Medium (17% of 15–35-
year-old women and men)  
 
Low (78% of 15–35-year-old 
women, 74% of 15–35-year-
old men) 
Two risk groups 
 
Core (propensity for short-
term partnerships, initially 
50% of 16-year-old women, 
60% of 16-year-old men)  
 
Non-core (prefer long-term 
partnership) 
 
Each year 4% of men, 8% of 
women switch from core to 
non-core  
Two risk groups 
 
High (propensity for concurrency and 
commercial sex, 35% of males, 25% of 
females) 
 
Low (no concurrent partnerships or 
commercial sex) 
 
Sexual debut occurs between ages of 
10-30, 50% higher rate in high-risk 
group. 
Partnership formation 
 Heterosexual only  
determined by sexual 
activity group, existing 




determined by sexual 
activity group, existing 




 determined by sexual 
activity group, existing 
partnership status, age 
difference  
Two types of partnerships 
possible: short-term (core) 
and long-term (non-core). 
Heterosexual only; 
determined by sexual activity group, 
existing partnership status and age of 
individual 
Three types of partnerships possible: 
short-term (non-cohabiting), long-term 
(cohabiting or marital), sex worker-
client  
Partnership duration 
 Mean 10 days for casual 
partnerships, 6.9 years 
(2519 days) for steady 
partnerships 
Mean 950 days if both 
partners in lowest activity 
group; lower means for 
higher activity groups 
Mean 14 days for short 
partnerships, 900 days for 
long partnerships and 
increases by 200 days each 
year  
Mean 180 days for short term, rates of 
dissolution of long term partnerships 
based on age specific divorce rates 
 
Concurrent partnerships 
 Core group can have up to 
two partners  
 
Non-core group has only 
one casual or steady partner 
at a time  
Highest activity group can 
have more than two 
concurrent partners  
 
Very low (but non-zero) 
probability of concurrent 
partnerships in lowest 
activity group 
5% of population can have 
two partners until 35 years 
(first partnership may be 
short or long, second 
partner always casual)  
 
All 35+ year olds prefer only 
one partner 
High-risk individuals can have up to 
two partners. High-risk men can 
engage in commercial sex in addition 
to two concurrent partnerships. 
 
Low-risk group are serially 
monogamous.   
Partner notification able to be modelled explicitly 
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